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Abstract

DISCOVERY OF MOR SELECTIVE, REVERSIBLE OPIOID ANTAGONIST FOR
POTENTIAL USE IN TREATMENT OF DRUG DEPENDENCE
Abdulmajeed M. Jali, M.S.
A thesis submitted in partial fulfillment of the requirements of Master of Science at
Virginia Commonwealth University.
Virginia Commonwealth University, 2017
Director: Dana E. Selley, Ph. D., Department of Pharmacology and Toxicology

Opioid dependence/addiction is a major public health problem that is
associated with multiple health and social costs. Pharmacotherapeutic treatment has
been relatively effective, but the risk of relapse after treatment remains high.
Naltrexone, an opioid antagonist, is FDA-approved for long-term maintenance
therapy to reduce relapse risk. However, naltrexone is accompanied by side-effects
that are due to lack of selectivity among opioid receptor types. Based on the
message-address concept and molecular modeling studies, 18 novel compounds
designed to bind selectively to the MOR based on interaction with a key aromatic
residue, were synthesized by our collaborators. The purpose of this study was to
identify MOR-selective antagonists from this series of compounds. Using radioligand

xii

and GTPgS binding assays in transfected cells and native tissues, two compounds
were discovered with the high MOR-selectivity and low efficacy required to serves as
lead ligands in future discovery efforts toward next-generation opioid antagonists.
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Chapter.1 Introduction
1.1 Opioids
The Sumerians are recognized to be the first people who harvested the opium
poppy plant around 3400 BC. They called it Hul Gil, the “joy plant. The opium resin,
which is derived from the poppy plant, Papaver somniferum, contains the active
opiate alkaloids morphine and codeine (Figure 1). Its first recorded use as an
analgesic was 2,500 years ago (Booth, 1999; Jaffe & Martin, 1990).

Figure 1. Chemical structures of morphine, codeine, and heroin
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Following the spread of the opium poppy’s cultivation and use throughout the globe,
several events occurred in the 19th century that led to increased understanding of
both the medicinal benefits and abuse and addiction liability of opioids, the latter of
which can cause devastating consequences. In 1806 Friedrich Serturner, a German
physician, was the first to isolate the active ingredients in opium and named it
morphine after Morpheus, the Greek god of dreams (Brownstein, 1993). Dr. Charles
Wood, a Scottish physician, invented the hypodermic needle and used it to inject
morphine to relieve pain. Morphine was first used as an adjunct to general
anesthetics when Claude Bernard used it for premedicating experimental animals.
He found that it reduced the required amount of chloroform to induce anesthesia. Dr.
Eduard Livenstein from Germany presented the first document that comprehensively
describes addiction to morphine, including withdrawal syndrome and relapse, and
argued that craving for morphine was a physiological response. In an attempt to
obtain a safer drug than morphine the English researcher C.R. Wright synthesized
3,6-diacetylmorphine in 1898 (Figure 1), also named “heroin”, which was briefly
promoted as more effective and less addictive than morphine before market
withdrawal (Booth, 1999; Brownstein, 1993; Musto, 1999).
The term opioid is now used to classify any compound that exhibits morphine-like
responses and includes naturally occurring opiates, synthetic and semi-synthetic
opioid agonists, partial agonists and antagonists, and endogenous opioid peptides
along with their synthetic analogues (Jaffe & Martin, 1990).

2

1.2 Opioid receptors
In 1973, three laboratories almost simultaneously demonstrated the presence
of specific opioid receptors by radioligand binding studies in homogenized
membrane fractions of rat brain (Pert & Snyder, 1973; Simonet al., 1973; Terenius,
1973). Consistent with earlier evidence from pharmacological studies, opioid
receptors were also shown to exist in the gastrointestinal system as illustrated by
Terenius (Terenius, 1972) and Synder and Creese (Creese & Snyder, 1975). The
concept of multiple opioid receptor types preceded their identification by two
decades when nalorphine produced biphasic effects in human clinical studies. Low
doses of nalorphine could block morphine analgesia, which however, was retrieved
at higher doses of nalorphine. Those findings could most readily be explained if
nalorphine acted on a second receptor (Snyder & Pasternak, 2003). More detailed
studies with different opioid drugs in the chronic spinal dog were conducted by
Martin et al. (Martin et al., 1976) and revealed the existence of three hypothesized
opioid receptor types. Each receptor type was named for the prototypical drug that
activated the receptor. The mu (µ) opioid receptor (MOR) was named for morphine,
the kappa opioid (k) receptor (KOR) was named for ketocyclazocine, and the sigma
(s) receptor was named for n-allylnormetazocine (SKF 10,047). Subsequent
purification and cloning studies uncovered that protein corresponding to s receptor
binding sites do not possess pharmacological properties of opioid receptors (Hanner
et al., 1996; Kekuda et al., 1996; Traynor & Elliott, 1993). Binding studies in rat brain
and studies utilizing isolated peripheral organ bioassays suggested the presence of
the delta opioid d receptor (DOR) which was selective for the synthetic enkephalin
analogue [D-Ala2, D-Leu5] encephalin (DADLE) (Lord, 1977). Two years later Chang
and Cuatrecasas (Chang and Cuatrecasas, 1979) confirmed the existence of opioid
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receptors with a purely d binding profile in NG 108-15 cells. The synthesis of highly
selective KOR ligands, such as U50,488, yielded more information on KOR binding
sites (Vonvoigtlander et al, 1983).
In the 1990s, multiple cloning studies definitively identified the three distinct
types of opioid receptors that were already hypothesized based on pharmacological
evidence. The first opioid receptor to be cloned was the DOR using cDNA from the
mouse DOR from NG108-15 (Evans et al., 1992). The cloning of MOR and KOR
followed by using their homology to the DOR (Chen et al., 1993; S. Li et al, 1993;
Meng et al., 1993; Minami et al., 1993; Wang et al., 1993).

1.3 Opioid peptides
The concept of endogenous opioid ligands arose after the discovery of opioid
receptors. This was supported by the production of analgesia during electrical
stimulation of specific brain regions (Mayer & Liebeskind, 1974). This analgesic
effect was blocked by naloxone, an opioid antagonist. Three major endogenous
opioid peptides have been characterized so far. Met-enkephalin and leu-enkephalin
were the first endogenous peptide to be isolated and sequenced (Hughes et al.,
1975). Both enkephalins are derived from one precursor polypeptide, proenkephalin,
and bind with the highest affinity to the DOR (Comb et al., 1982; Hughes et al., 1975;
Traynor & Elliott, 1993). The second one is b-endorphin, discovered by Li et al. in
1976, which binds to the MOR and DOR with relatively equal affinity, and derived
from the polypeptide precursor, pro-opiomelanocortin (POMC) (C. H. Li et al., 1976).
The third endogenous peptide is dynorphin, which has the highest affinity for KOR
and derived from the polypeptide prodynorphin (Chavkin & Goldstein, 1981;
Goldstein et al., 1979). All opioid peptides are cleaved from their larger polypeptide
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precursors by proteolytic cleavage at dibasic residues, and expression of the gene
encoding each particular precursor determines the opioid peptide(s) that is used by
each particular opioidergic cell (Froehlich, 1997) (Figure 2).

Figure 2. Three major families of opioid peptides, B-endorphin, Met-enkephalin and
Leu-enkephalin, Dyndorphin A, are derived from distinct precursor molecules and
are encoded by three different genes (Clinical Gate, 2015).

1.4 Physiological effects
Due in part to the widespread distribution of opioid receptors in the brain,
opioids, such as morphine, are involved in multiple physiological effects. Several
studies have shown that most of the clinically relevant effects of opioids are
mediated through the MOR, which has been confirmed in knockout mice genetically
lacking the MOR (Kieffer, 1999). The major therapeutic effect induced by opioid
agonists is analgesia. Opioids not only increase the threshold of stimulus intensity
required for detection of a noxious stimulus, but also alter pain perception in CNS;
therefore they alleviate the negative emotional state that occurs during pain (Jaffe &

5

Martin, 1990). Beyond alleviation of negative emotions, euphoria has been reported
among a large portion of patients, yet some patients experience dysphoria. It is
thought that the MOR in the ventral tegmental area (VTA) and nucleus accumbens
(NAc) is responsible for mediating reward, a common response to MOR agonists
and other drugs of abuse (V David & Cazala, 2000; Fields & Margolis, 2015; Jaffe &
Martin, 1990; Olmstead & Franklin, 1997; Y. Zhang et al., 2009). Opioids also display
antitussive effects due to inhibition of cough reflex in the medulla (Jaffe & Martin,
1990). One of the therapeutic limitations of opioids is respiratory depression, which
results from inhibition of respiratory centers in the brainstem and accounts for the
potential for lethality in opioid overdose (Pattinson, 2008). Constipation is another
common side effect. The mechanism by which constipation occurs is decreasing
propulsive bowel contractions and increasing non-propulsion contractions of
intestinal smooth muscle, along with increasing anal sphincter tone, mainly through
effects on the enteric nervous system. Other opioid physiological effects include
miosis, histamine release, prolactin release, ACTH stimulation, LH and oxytocin
inhibition, emesis, sedation and convulsion, the latter two of which occur mainly at
relatively high doses (Jaffe & Martin, 1990).
Fortunately, tolerance develops to the lethal effects of opioids, but also to
analgesia. Very little tolerance develops to constipation and miosis. MORs also
mediate opioid dependence, which leads to the withdrawal syndrome upon the
abrupt reomval of the agonist or precipitation by administration of an antagonist.
Also, cross-tolerance has been observed between different opioid agonists, further
supporting the evidence that the effects of most clinically relevant opioid agonists are
mediated through the same receptor: MOR (Jaffe & Martin, 1990).
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Opioids have a high degree of abuse liability, and it is well known that chronic
use of opioids can lead to tolerance, dependence, and in many cases, addiction.
Addiction can be broadly defined as a state of continued, compulsive, relapsing
drug-seeking behavior even in the face of negative emotional, social, legal and
monetary consequences. A major focus in opioid research has been the discovery of
novel drugs that can effectively treat opioid addiction. Therefore, a better
understanding of opioid receptor signaling could provide useful information for
discovery of novel drugs that are useful in the treatment of opioids dependence or
addiction.

1.5 Opioid receptor signaling
Opioids produce their effects through the activation of opioid receptors which
belong to G-Protein Coupled Receptor (GPCRs) Superfamily. GPCRs are the largest
class of membrane proteins in the human genome. GPCRs share common features;
each consists of a single polypeptide with an extracellular N-terminus, an
intracellular C-terminus, and seven hydrophobic transmembrane domains (TM1TM7) linked by three intracellular loops (IL1-IL3) and three extracellular loops (EL1EL3). Opioid receptors belong to the opsin family, or rhodopsin-like family
(Mombaerts, 2004). GPCRs produce intracellular signaling primarily by the activation
of guanine nucleotide-binding regulatory proteins (G-proteins). G-proteins are
heterotrimeric proteins composed of a, b, and g subunits. Those subunits are made
up of a large family and can form several combinations that reflect the complexity of
transduction of signals via G-proteins. There are 18 genes for the a subunits, which
are categorized into four families, as, a12, ai, and aq. b and g subunits have 5 and 12
known types, respectively. These different subunits have a substantial role in
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signaling as they can be stimulatory or inhibitory based on the G-protein family to
which they coupled (Hamm, 1998; Hildebrandt, 1997).
Opioid receptors are coupled to the inhibitory type of G-proteins, Gi/o. They
can be activated by either endogenous or exogenous ligands, such as b-endorphin
or morphine. The binding of an agonist to a GPCR stabilizes an active conformation
of the receptor. This will facilitate the release of guanosine diphosphate (GDP) that is
prebound to the Ga subunit for cytoplasmic guanosine triphosphate (GTP), a
process known as guanine nucleotide exchange (Tuteja, 2009). The release of GDP
from the Ga subunit is caused by an increase in GDP dissociation rate (Florio &
Sternweis, 1989; Lorenzen et al., 1993), possibly culminating in decreased GDP
affinity (Breivogel et al., 1998; Selley et al., 1997). After the binding of GTP, the Ga
subunit dissociates from the bg subunits, which remain associated with each other as
a heterodimer, and both the a and bg subunits become free to interact with various
effectors and either increase or decrease their activity depending on the specific Gprotein subunit and effector protein. The termination of G-protein activity is controlled
by the intrinsic GTPase activity of the Ga subunit, which catalyzes the hydrolysis of
GTP to GDP, therefore inactivating G-protein signaling and allowing the
reassociation of Ga with the Gbg complex (Tuteja, 2009) (Figure 3).
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Figure 3. Schematic representation of G-protein activation/inactivation cycle (Smith
et al., 2010).
Effectors that are modulated by Gi/o include inhibition of adenylyl cyclase,
activation of inwardly rectifying potassium channels (GIRK), inhibition of calcium
channels, especially the N and P/Q types, activation of phospholipases C/A2,
Mitogen-activated protein kinases (MAPK), and Phosphoinositide 3-kinases (PI3) . It
was initially thought that bg subunit did not directly modulate effector activity, but
later studies revealed that it can directly modulate effector activity either positively or
negatively (Tuteja, 2009). There are also other intracellular kinases that are indirectly
modulated by G-proteins. The phosphorylation of active GPCRs, including opioid
receptors, by G-protein Coupled Receptor Kinases (GRK) leads to desensitization of
GPCR-mediated G-protein activation and coupling of the receptor to the clathrinmediated enodocyitc process, which leads to GPCR internalization. b-arrestins can
also act as a scaffold to recruit alternative downstream signaling pathway such as
MAPK or protein kinase B (Akt). The MAPK family is composed of 12-15 gene
9

products with the most well-described being extracellular signal-regulated kinases 1
and 2 (ERK1/2) (Al-Hasani & Bruchas, 2011).

1.6 In vitro studies of opioids
1.6.1 Radioligand binding
The first step in initiating a cellular response is the binding interaction between
a ligand and a receptor. Therefore, the relative affinity of a given ligand for the target
receptor versus other related receptors will in part determine its selectivity of action.
Our radioligand binding studies were designed to determine the binding affinity of
novel ligands for each of the three major opioid receptor types, MOR, KOR and
DOR, and to compare the relative binding affinities of each ligand between receptor
types to determine the selectivity for each receptor. To accomplish this goal, we
utilized indirect competition binding assays. Radiolabeled ligands that reversibly bind
to the desired receptor were used to label each receptor of interest, mouse receptors
that are stably expressed in Chinese hamster ovary (CHO) cells, and a range of
concentrations of each novel compound was added to determine the competition
binding affinity for each receptor type. This approach avoids the need to radiolabel
each novel compound, and can be used to rapidly screen multiple compounds. We
used mouse receptors because our collaborators will use mice for in vivo evaluation
of the novel ligands. Thus, we can correlate the in vitro and in vivo data with the
same species. The use of heterologously transfected cell lines allows for a high level
of receptor expression, which provides a high ratio of specific to non-specific binding,
and avoids the complication of co-expression of additional opioid receptor types in
each cell line. A detailed explanation of the radioligand binding assay is provided in
Chapter 2. One disadvantage of all ligand-receptor binding assays is that they
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cannot determine the functional activity of the ligand when it binds to the receptor of
interest. For this, an assay of functional receptor activity must be conducted, as
introduced in the next section.

1.6.2 Functional activity of opioid ligands
As mentioned in section 1.4, the biological responses of opioids are mainly
mediated by the MOR and our novel ligands of interest were designed to bind
selectively to the MOR. Therefore, the efficacies of our novel ligands were tested in
the same MOR-expressing CHO cells (mMOR-CHO) used in the MOR radioligand
binding assays. Further comparative studies were also conducted in mouse
thalamus, which expresses a high density of MOR with relatively low expression of
other opioid receptor types, in order to determine the relative efficacy of our novel
lead compounds compared to one of our first-generation lead compounds, 17cyclopropylmethyl-3,14b-dihydroxy-4,5 a-epoxy-6a-[(3'isoquinolyl)acetamido]morphinan (NAQ), in a more native biological system.
As previously described in section 1.5, the MOR is a GPCR that is coupled
mainly to the Gi/o subfamily of G-proteins. Because there are multiple spatial and
temporal cellular events that occur between the binding of an agonist to a receptor
and the production of a biological response, it is critical to consider whether to
measure a proximal or distal signaling step in signal transduction following GPCR
activation. Multiple cellular signaling events at various steps in MOR signaling
pathways have been examined to assess the efficacy of agonists, and several of
these are briefly discussed below.
Intracellular Ca+2 is a second messenger downstream in the signaling
pathway for certain GPCRs. Unlike receptors that are naturally coupled to activation
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of Gaq,, Gai/o-coupled receptors cannot generally induce a ligand-dependent
increase in intracellular Ca+2. In order for Gi/o to cause a robust increase in
intracellular Ca+2 in the cellular model used in this study, transfection of a chimeric
Gaq -protein (Gaqi5 or Gaqo5) containing the 5-residue C-terminal sequence of Gai/o
that is required for receptor coupling or a promiscuous G-protein (Ga16 or Ga15) is
required (R. Zhang & Xie, 2012). This requires additional manipulation of the cell
system. In addition, Ca2+ release is three steps downstream in the signaling
pathway, which includes G-protein mediated activation of the effector phospholipase
C, synthesis of the second messenger inositol triphosphate (IP3), and IP3-induced
release of Ca2+ from the endoplasmic reticulum. Therefore, there is substantial signal
amplification that occurs between G-protein activation and stimulation of intracellular
Ca+2 release (Tuteja, 2009; Yan et al., 2016). In contrast, measurement of an event
that is proximal to the receptor and therefore subjected to minimal signal
amplification would provide better discrimination between full and partial agonists
(Keen, 1991).
Adenylyl cyclase (AC) is a major target for the MOR so most early functional
GPCR assays measured production of the G-protein mediated second messenger,
cyclic adenosine monophosphate (cAMP) (R. Zhang & Xie, 2012). G-proteinmediated modulation of AC activity results in a direct measurement of the synthesis
of cAMP. This is in contrast to the intracellular Ca2+ release assay, which measures
the activity of Ca2+ channels that are targets of the second messenger, IP3.
Therefore, measurement of AC-generated cAMP has one less amplification step
than measurement of intracellular Ca2+ responses. MOR-mediated inhibition of AC
results in reduced production of cAMP (Traynor & Elliott, 1993). Generally, full MOR
agonists produce maximal inhibition of cAMP, whereas partial agonists produce
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partial inhibition of cAMP (Blake et al., 1997). However, this approach could also
report misleading results, as it has been demonstrated that signal amplification
occurs between GPCR-mediated activation of G-protein and inhibition of adenylyl
cyclase, which would make it difficult to discriminate between full agonists and partial
agonists of relatively high intrinsic efficacy (Costa et al., 1988; Tuteja, 2009; R.
Zhang & Xie, 2012). Therefore, an upstream step, such as direct measurement of Gprotein activity, would convey more accurate assessment of opioid ligand efficacy.
Previous studies used the activity of Ga-associated low Km GTPase as an
indicator for G-protein activation. This approach measures the increase in GTPase
activity of the Ga subunit following its activation by the receptor (Koski & Klee, 1981).
This method, in fact, is not ideal because it measures the hydrolysis of GTP that
occurs after guanine nucleotide exchange-induced activation, which is an indirect
method to measure G-protein activation. This approach provides a low signal to
noise ratio because of the high level of GTP hydrolysis by non-Ga enzymatic activity,
such as ATPases. It has also been shown that GTP hydrolysis can be influenced by
factors that are not relevant to G-protein activation because they affect the GTPase
step subsequent to G-protein activation (Selley et al., 1993). Therefore, a more direct
approach is required for accurate measurement of GPCR activation.
The earliest cellular event subsequent to GPCR activation is the exchange of
GTP for prebound GDP on the Ga subunit. This event is not subjected to
amplification other than the initial amplification step that can occur between GPCR
and G-protein. Upon the occupation of the MOR by an agonist, GTP will replace
GDP on the a subunit leading to dissociation of Ga-GTP from Gbg and subsequent
modulation of downstream effectors. GTPase terminates the activation cycle by
hydrolyzing GTP and thus restores the Ga-GDP subunit, which then reassociates
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with the bg dimer, terminating its interaction with effectors. The ability to measure
receptor-stimulated formation of the Ga-GTP complex provides a precise evaluation
of opioid efficacy. The [35S]GTPgS, an analogue of GTP, membrane binding
technique has been widely used to measure agonist stimulated G-protein activation
by GPCRs. Indeed, this technique is experimentally more suitable for Gi/o- coupled
receptors because Gi/o is the most abundant G-protein subfamily in many cells and
has the fastest GDP/GTP exchange rate among other G-proteins (C. Harrison &
Traynor, 2003; R. Zhang & Xie, 2012). Thus, the [35S]GTPgS membrane binding
technique is the best available approach to determine the efficacy of opioid ligands
on opioid receptors, including the MOR. [35S]GTPgS is an analogue of GTP upon
which an oxygen on the terminal phosphate is replaced with a sulphur, thus
rendering the analogue resistant to hydrolysis by GTPase because of the covalent
bond formation between the terminal phosphate and sulphur. [35S]-labeled GTPgS
competes with GTP for binding to the Ga subunit and allows the measurement of
accumulation of bound [35S]GTPgS due to the stability of the Ga-[35S]GTPgS
complex. When MOR are occupied by a ligand, the receptor will stimulate guanine
nucleotide exchange on MOR-coupled G-proteins to an extent proportional to the
occupancy of the receptor and the efficacy of the ligand, and the maximal magnitude
of MOR-stimulated [35S]GTPgS binding can be used as a measure of ligand efficacy
(C. Harrison & Traynor, 2003) (Figure 4).
The radiolabeled [35S]GTPgS is added to membrane homogenates in the
presence of excess GDP and Na+, which play a major role in GPCR activation. Our
laboratory has published a study on the effect of GDP on various MOR ligands in
mMOR-CHO cells and rat thalamus. It was found that addition of excess GDP
increased the signal to noise ratio by suppressing the spontaneous Gi/o activity in the
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absence of an agonist. Also, at 10-20 µM GDP in mMOR-CHO and 30 µm in the
thalamus the efficacy of full and partial agonists with high to low relative efficacy
could be clearly discriminated from each other (Selley et al., 1997). Furthermore, it
has been shown that Na+ can inhibit basal [35S]GTPgS binding by reducing
spontaneous receptor-stimulated activity in mMOR-CHO cells and thalamus.
Similarly to GDP, increasing the concentration of Na+ magnified the relative efficacy
differences among MOR agonists. 100 nM of Na+ produced a maximal difference in
relative efficacy among full and partial MOR agonists (Selley et al., 2000). Therefore,
having these conditions in our assay will optimize the agonist-stimulated binding of
[35S]GTPgS and provide an accurate assessment of the relative efficacy of our novel
ligands.
Prior to the widespread availability of the cloned opioid receptors, use of the
[35S]GTPgS membrane binding technique with opioids was limited to tissues
endogenously expressing the receptor, such as SH-SY5Y tumor cell line (Traynor &
Nahorski, 1995) or brain homogenates (Sim et al., 1995). A major disadvantage of
these two systems that they frequently express two or more opioid receptors, making
it difficult to determine the efficacy of nonselective opioid agonists. When opioid
receptors were cloned in the 1990s, as discussed in section 1.2, not only did it help
to better understand the anatomical expression pattern of opioid receptors, but also
allowed the transfection of the receptors of interest into cell lines. The choice of a cell
line is based on certain criteria; the main ones are lack of endogenous expression of
opioid receptors, fast growth rate, easy handling, surface-adherence, and ease of
transfection. The Chinese hamster ovary cell line possess these features (Pan,
2003), and was therefore chosen for use in this project.
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On the other hand, it has been demonstrated previously in our laboratory that
the level of receptor expression can affect the relative efficacy of MOR agonists.
mMOR-CHO cells express MOR density higher than in native tissue such as the
rodent thalamus. This difference in receptor expression is reflected in the efficacy of
opioid agonists between mMOR-CHO cells and thalamus whereby some apparent
full agonists in mMOR-CHO cells acted as partial agonists in rat thalamus, and
partial agonists in mMOR-CHO cells acted as pure antagonists in rat thalamus. For
example, morphine acted as a full MOR agonist in mMOR-CHO cells, but acted as a
moderate efficacy partial agonist in thalamus. Another example is levallorphan,
which acted as a partial agonist in mMOR-CHO cells and pure antagonist in
thalamus (Selley et al, 1998; Selley et al., 1997). Hence, we tested our lead
compounds in mouse thalamus to obtain results under more native conditions.
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Figure 4. Schematic representation of [35S]GTPgS binding assay. Relative efficacies
of GPCR ligands can be determined in vitro using the [35S]GTPgS binding assay.
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1.7 MOR expression and role in opioid abuse and addiction
The majority of clinical effects of opioids are mediated mainly by the MOR.
Evidence in favor of this comes from in vivo experiments with antisense knockdown
of the MOR (Rossi et al., 1995) and in mice with genetic deletion of the MOR
(Kieffer, 1999). Data from these studies revealed that both antinociceptive and
abuse-related effects of opioids are abolished or greatly attenuated in MORknockout mice. These studies confirmed years of prior research with moderately
selective opioid antagonists. For example, naloxone blocks the analgesia produced
by morphine with much lower dose than blocking analgesia produced by the
selective KOR agonist U-50,488 (Vonvoigtlander et al., 1983).
Opioid receptor cloning helped to map the anatomy of opioid receptor mRNAs
in connection with their binding sites in the brain. The MOR is widely distributed
throughout the CNS. They are found in forebrain, midbrain, hindbrain and spinal
cord. The richest regions are neocortex, caudate putamen, nucleus accumbens,
thalamus, hippocampus, amygdala, inferior and superior colliculi, ventral tegmental
area (VTA), periaqueductal gray (PAG), locus coeruleus, nucleus tractus solitarius,
spinal trigeminal nucleus and dorsal horn of the spinal cord (Mansour et al 1995;
Satoh & Minami, 1995). The localization of the MOR is in agreement with the
functions of the regions that mediate the clinical effects upon activation of the MOR.
Opioids have been used for the treatment of moderate to severe pain and
related disorders for thousands of years. Commonly used opioids for pain treatment
include morphine and codeine (natural opioids), methadone, hydrocodone, fentanyl,
oxycodone, and buprenorphine. The choice of opioid is based on the conditions of
particular patient and desired route of administration, but in general, higher efficacy
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opioids are used to treat more severe pain than lower efficacy opioids. The
advantage of opioids over other painkillers is that they not only block the perception
of pain but also inhibit the pain-related negative emotional status of the patient,
which improves the quality of their lives, making opioids a major drug of choice for
pain treatment. The localization of the MOR in the midbrain is a major factor in
mediating opioid-induced analgesia. When MORs are activated by an agonist, they
induce analgesia either directly or indirectly. The direct way is mediated by inhibiting
the ascending transmission of neurons from substantia gelatinosa in the dorsal horn
of the spinal cord and peripheral nociceptive afferent neurons, thus decreasing
nociceptive transmission from the periphery. Another mechanism of opioid-induced
analgesia is indirectly stimulating the descending inhibitory pathway by acting on
PAG and nucleus reticularis paragigantocellularis (NRPG). This results in higher
neuronal activity through the nucleus raphe magnus, thus increasing the activation of
5-hydroxytryptamine and enkephalin-containing neurons which connect directly with
the substantial gelatinosa of the dorsal horn. The net effect of this pathway is an
inhibition of nociceptive transmission from the periphery to thalamus (Pathan &
Williams, 2012).
Reward is another common response that is mediated by MORs that are
located in VTA and NAc. The mesolimbic dopaminergic system (Figure 5) is
considered a major player in mediating the positive reinforcing effects of opioids (Le
Merrer et al., 2009). Several studies have shown that opioids induce positive
reinforcement by increasing the level of dopamine in the mesolimbic system (Bardo,
1998; Koob, 1992; Shippenberg & Elmer, 1998; van Ree et al., 1999), and more
recent studies have confirmed it is the MOR that, upon activation by opioids,
produces the positive reward (Vincent David et al., 2008; Terashvili et al., 2004;
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Zangen et al., 2002). Dopamine neurons of VTA project to other brain regions that
are involved in reward-relevant function, including NAc, amygdala, hippocampus and
prefrontal cortex. In addition to dopamine neurons, VTA contains GABA and
glutamate neurons, which project to many of the same mesolimbic targets as the
dopamine neurons. The mechanism by which the MOR excites VTA dopamine
neurons is through inhibiting GABA interneurons that synapse on dopaminergic
neurons in VTA. The elimination of tonic GABAergic inhibition by the MOR results
from the activation of GIRK channels or inhibition of N and P/Q calcium channels on
GABA neurons, which are major effectors of Gai/o (Fields & Margolis, 2015).
Consequently, synaptic dopamine levels will increase in terminal field regions due to
a lack of suppression by GABA. Reward, or euphoria, is argued to be an emotional
side effect of pain treatment by opioids, although it undoubtedly plays a role in
inhibiting the negative emotional effects of pain (Miller et al., 2015).
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Figure 5. VTA-NAc reward circuit in the mesolimbic system (Russo & Nestler, 2013).
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Despite the clinical benefits, MORs also account for multiple side effects
associated with opioid use. These side effects put restrictions on opioid therapeutic
use. The side effects can be divided into peripheral side effects, including
constipation, urinary retention, and bronchospasm, or central side effects, including
nausea, sedation, respiratory depression, and hypotension, all of which can severely
affect the patients’ quality of life and opioid clinical utility (Al-Hasani & Bruchas,
2011). One of the most troublesome side effects of opioids is tolerance, which is
defined as the need to increase the dose of a drug to obtain the same response.
Tolerance results from chronic opioid agonist use, especially at relatively high doses
such as those often needed to treat severe pain. Even though tolerance develops to
all actions of the MOR, the rate of tolerance development differs between different
responses. For instance, tolerance to analgesia develops at a somewhat faster pace
than to respiratory depression and constipation, leading to narrowing therapeutic
index with chronic opioids administration (Pasternak & Pan, 2013). Repetitive use of
opioids can also lead to physical dependence and/or addiction (Al-Hasani &
Bruchas, 2011; Feng et al., 2012).
Opioid tolerance encompasses a diverse range of molecular and cellular
mechanisms making it difficult to be incorporated into a unified theory. Certain
studies suggested that NMDA receptors, enkephalin systems, and P-glycoprotein
play a role in opioid tolerance (Pasternak & Pan, 2013). Also, some in vitro studies
reported that chronic opioid exposure can lead to opioid receptor desensitization,
internalization and downregulation, producing cellular tolerance (Dang & Christie,
2012; R. S. Harrison et al., 2010). Several studies revealed that following chronic in
vivo treatment with morphine or heroin, MORs could be desensitized (uncoupled
from the G-protein signaling pathway) as indicated by a reduction in agonist-
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stimulated [35S]GTPgS binding in the absence of downregulation of MOR binding
sites (Sim-Selley et al., 2000, 2007; Sim et al., 1996). These studies further showed
that MORs expressed in different brain regions were differentially sensitive to
agonist-induced desensitization, such that desensitization occurred more readily in
brainstem regions and spinal cord than in forebrain regions. Furthermore, it has been
reported that different MOR agonists can differentially internalize the MOR, and that
MOR internalization can enhance MOR re-sensitization and therefore plays a role in
opposing tolerance development (Waldhoer et al., 2004).
One widely observed cellular adaptation associated with opioid
dependence/addiction is the elevation of cAMP levels subsequent to chronic MOR
agonist exposure. This elevation reflects cellular adaptation, rather than receptor
desensitization or downregulation, to the presence of MOR agonists. This response
includes upregulation of adenylyl cyclase types I and VIII, and increases in the
activity of protein kinase A (PKA) and cAMP response element binding (CREB)
protein (Nestler 1996). Consequently, the cAMP/PKA pathway returns to a normal
level in chronic opioid exposure states. Upon the removal of the agonist or
administration of an antagonist, cAMP overshoot takes place and is recognized as a
potential mechanism for withdrawal symptoms (Nestler, 1996; Zachariou et al.,
2008). Elevation of cAMP levels has been seen in brain regions where MORs are
expressed, such as locus coeruleus, NAc, and striatal neurons (Fan et al., 2009;
Zachariou et al., 2008). In addition to CREB, DFosB is another transcriptional factor
that has a role in opioid dependence. DFosB is a truncated splice variant of FosB
that is stable and gradually accumulates with repeated administration of drugs of
abuse in NAc, hippocampus, and dorsal striatum. Unlike CREB, which is related to
withdrawal symptoms by the activation of dynorphin/KOR pathway resulting in
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dysphoria (Knoll et al., 2011), DFosB is related to pro-reward effects. The stability of
and inhibition of dynorphin by DFosB are partially associated with the sensitization to
the rewarding effects of opioids, and might contribute to relapse (Nestler, 2013;
Zachariou et al., 2006).

1.8 Pharmacotherapy options
The issue of opioid tolerance and dependence/addiction has been a growing
problem in the US over the past two decades. The addiction liability of opioids is very
high among people who use heroin or prescription opioids (Bart, 2012). Whether
opioid addiction arises from chronic use during pain treatment (Ballantyne &
LaForge, 2007) or access to illicit opioids on the streets, the negative social, health
and economic consequences of opioid addiction point to the need for an effective
drug treatment. In 2015, opioids were in the top of overdose deaths caused by drugs
of abuse with 33,000 out of 52,000 deaths (Rudd et al., 2016). Moreover, the number
of overdose deaths from opioids, both prescription and heroin, went up by 2.5-fold
from 2002 to 2015 (NIDA, 2014). Also, substance abuse disorders cost the nation
approximately $600 billion yearly. Effective pharmacotherapeutic treatments have
shown a reduction in the costs associated with opioid addiction. For example, one
year of methadone maintenance treatment costs an average of $4,700 per patient,
whereas one year of imprisonment costs approximately $24,000 per person (Volkow,
2012).
The currently approved treatments by FDA for opioid dependence are based
on the long-term maintenance therapy with either an agonist, partial or full, or an
antagonist. The long-term agonist maintenance therapies include the MOR full
agonist, methadone, and the MOR partial agonist, buprenorphine. Both drugs are
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synthetics and have a long half-life that allows one daily dose, lasting up to 28 hours
for methadone and 37 hours for buprenorphine (Bart, 2012). Methadone and
buprenorphine are typically used as replacement therapy for opioid dependence.
Opioid-withdrawal syndromes occur when there is a rapid decline in blood drug level
following the termination of repeated exposure, thus using a MOR agonist will
diminish withdrawal symptoms by maintaining a steady-state level of drug that
makes patients feel essentially normal, rather than euphoric or dysphoric. After
stabilizing patients on a dose that alleviates withdrawal symptoms, patients can be
tapered off the drug until detoxification is achieved (Schuckit, 2016). Yet, a large
portion (40-60%) of patients relapse to abusing either heroin or other opioids
(Volkow, 2012). Like most opioid agonists, methadone and buprenorphine have the
potential to cause respiratory depression when overdosed (especially with the higher
efficacy agonist, methadone), and to be abused. Also, cardiac side effects have
been associated with methadone during induction period or upon discontinuation
(Bart, 2012).
Another disadvantage of long-term agonist maintenance therapy is the
potential for immune system impairment. Functional, binding, and molecular studies
indicate the expression of opioid receptors on cells from the immune system. Opioids
may act like cytokines to modulate the immune system through interaction with
opioid receptors, either centrally or peripherally, yet the mechanism is complicated
and not well understood (Feng et al., 2012). Nonetheless, evidence suggests an
immunosuppressive role of opioids. One study showed a significant reduction in
natural killer cell activity when rats were injected systemically with morphine, and
naltrexone fully reversed this effect (Vallejo et al., 2004). A similar effect was seen
on T-lymphocyte proliferation in rats following morphine injection (Flores et al.,
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1994). This immunosuppressive action of opioids is mediated by the MOR, as
confirmed by a study in which morphine did not affect immune system function in
mice lacking the MOR (Vallejo et al., 2004). Moreover, the prevalence of human
immunodeficiency virus (HIV), hepatitis C virus (HCV) and other infectious diseases
is high among opioids abusers, both in injecting or non-injecting individuals. These
diseases are transferred by sharing contaminated injection equipment and by
involving in risky sexual behavior sometimes associated with drug use (Volkow,
2012). In fact, one study by Mahajan et al (Mahajan et al., 2002) explored the
significant role of MOR agonists in the pathogenesis of HIV. Using an astrocytoma
cell line and normal human astrocytes, this study showed that morphine inhibited
local production of HIV-1 protective chemokines leading to encephalopathy.
Morphine, also, enhanced the expression of an HIV-1 entry co-receptor gene within
the CNS. These effects were reversed by the selective MOR antagonist, bfenaprexamine, indicating a primary role of the MOR in the susceptibility of the CNS
to HIV infection. Therefore, the immune system of individuals who are on agonist
maintenance therapy or in a relapse period will be affected by the persistent
activation of the MOR.
Opioid agonists have also shown a paradoxical effect, in which they can
activate pronociceptive systems leading to pain hypersensitivity and short-term
tolerance. Instead of analgesia, repeated use of opioid agonists can induce
hyperalgesia, which is defined as a reduction in pain threshold. Evidence suggests
that opioids can stimulate certain effectors in opposition to their inhibitory role, at
ultralow doses or after chronic agonist exposure (Ghelardini et al., 2015). In a study
with cultured dorsal root ganglion neurons, micromolar concentrations of opioid
agonists decreased the action potential duration, while nanomolar concentrations
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increased it (Shen & Crain, 1989). In a clinical study using a cold pressor test for
detecting pain threshold in patients on methadone maintenance therapy (MMT) and
normal subjects, patients on MMT detected pain earlier and were less tolerant to
pain than normal individuals (Doverty et al., 2001), implying that prolonged activation
of the MOR was related to opioid-induced hyperalgesia. This was supported by Clark
et al (Li et al., 2001) using the mouse strain, CXBK, with reduced MOR expression in
the CNS, which showed that the when the CXBK mice were injected with morphine
and there was no signs of hyperalgesia.
To avoid the aforementioned disadvantages and to prevent relapse, patients
can be switched to an antagonist maintenance therapy. The only opioid antagonist
approved by the FDA for the treatment of opioid addiction/dependence is naltrexone
(NTX). It is a semi-synthetic antagonist that was synthesized as a congener of
oxymorphone in the 1960s. Compared to methadone or buprenorphine, NTX
possesses essentially zero intrinsic efficacy at the MOR; thus it will not induce any
side effects that results from MOR activation (Bart, 2012). Patients do not develop
tolerance to nor dependence on NTX. Also, NTX is not only approved for relapse
prevention of opioid dependence but is also used in the treatment of alcohol
dependence (Stotts et al.,2009). Moreover, NTX lacks addiction liability, is not
reinforcing, and has no potential for abuse or diversion for unprescribed use. It can
also block the effect of parenterally administered heroin, hydromorphone or
morphine for 24, 48, and 72 hours, respectively (Tai and Blaine, 1997). The main
lethal effect of opioid agonist overdose is respiratory depression, which is not caused
by NTX when overdosed. The hypothesis behind using NTX maintenance therapy is
to prevent drug-induced relapse and thereby minimize the effects of factors that
cause negative reinforcement, such as drug-associated cues and social stressors.
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With NTX occupying the MOR, patients will not be able to relieve the resulting
negative emotional state through opioid use, hence the behavior of relapsing will
ultimately cease (Bart, 2012). Unlike methadone and buprenorphine, NTX is
relatively safe for patients with HCV, HIV, and who consume large amounts of
alcohol (Schuckit, 2016). To avoid precipitating withdrawal symptoms, individuals
need to be tapered off with an agonist first and then switched to NTX to prevent
relapse. The antagonist maintenance therapy requires a shorter period of time
required for patients to be on drug. A clinical study showed that 6-month retention
rates in treatment following extended release NTX are similar to one-year retention
in methadone maintenance (Stotts et al., 2009).
One of the long-term effects of NTX is the upregulation of MOR. It has been
found that after chronic exposure to NTX, the density of MOR increased in brain and
a 7315c cells model. This was demonstrated by the increased number of maximum
binding sites for MOR agonists, but there was no change in the affinity of MOR for
MOR agonists. The potency of the MOR agonists was not influenced in an AC
inhibition assay, but the efficacy increased. This could be due to the upregulated
MOR that can activate more G-proteins subunits which can cause greater maximal
inhibition of AC (Côté et al., 1993). Although it is unclear whether MOR upregulation
by chronic NTX treatment occurs equally among CNS regions, one implication of
these findings is that sensitization to a subset of MOR agonist effects could occur
following such treatment. While this could pose some potential risks depending on
which opioid actions become sensitized, one could also speculate that it might lead
to improvement in MOR-mediated functions of the endogenous opioid system.
The most common reported side effects of NTX are nausea, headache,
depression and dysphoria (Stotts et al., 2009). These side effects are thought to be
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caused by the non-selectivity of NTX for opioid receptors. The selectivity of NTX for
MOR over DOR is fairly high, with 435-fold selectivity (Ki= 0.33 and 143.5 nM,
respectively), but the selectivity over KOR is modest, with only a 4.4-fold selectivity
ratio (KOR Ki= 1.44 nM). Because a large dose of NTX is required to outcompete
self-administered agonists and prevent relapse, there can be off-target effects. NTX
can bind to DOR and KOR at sufficiently high doses. The intrinsic efficacy of NTX at
KOR is higher than at MOR and DOR; NTX is a partial agonist at KOR (Bidlack,
2014). The activation of KOR in VTA is linked with dysphoria due to inhibition of
dopamine release (Lalanne et al., 2014). Human and animal studies reported
dysphoric effects upon activation of KOR by either endogenous or exogenous
agonists (Lalanne et al., 2014). While NTX is a partial agonist at KOR, it is an
antagonist at DOR, which has a positive role in modulating mood. Mice with genetic
knockout or antagonism of the DOR displayed depressive-like behavior and anxiety,
whereas activation of the enkephalin/DOR system enhanced mood activity (Lutz &
Kieffer, 2013). Therefore, it is possible that relatively high doses of NTX could
produce pro-depressive, dysphoric effects via partial agonism at KOR or antagonism
of DOR, although thus far there is little direct evidence of these hypothetical
mechanisms. However, it should also be noted that blocking peripheral KOR has
been associated with cardiac side effects, as KORs are expressed in heart tissue,
but their physiological role is not well understood (Peng et al., 2012). A human study
with the selective KOR antagonist JDTic, a 4-phenylpiperidine derivative ((3R)-7hydroxy-N-[(2S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]-3methylbutan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide), showed that
bradycardia and ventricular tachycardia were produced in the JDTic group (Chavkin
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& Martinez, 2015). Consequently, with a drug that can selectively antagonize MOR,
potentially serious cardiac side effects could be avoided.

Several drug discovery attempts have been conducted to avoid these side
effects of NTX by synthesizing a compound with better MOR selectivity. However,
the current MOR antagonists do not have the desired characteristics for clinical use.
For example, cyprodime has a lower affinity for MOR than NTX or naloxone. Also,
cyprdime has only moderate selectivity for MOR over DOR and KOR (Ki value ratios
are approximately 45 over KOR and 40 over DOR). Other MOR-selective
antagonists act as irreversible antagonists, such as b-funaltrexamine and
colcinamox, which are not favored because of covalent bond formation with the
receptor that will lead to a long-term reduction of available receptors. Even though
CTAP and CTOP are MOR-selective antagonists, the fact that they are peptides
limits their medical application due to poor bioavailability when given orally or
parenterally. Peptides are vulnerable to metabolic inactivation and elimination, and
most cannot penetrate blood-brain barrier (Li et al., 2009). Like NTX, naloxone is a
relatively non-selective opioid antagonist, but is short-acting and useful for reversing
opioid-induced respiratory depression by IV injection (Dorp et al., 2007). However, it
has very poor oral bioavailability, making it impractical for use in long-term
maintenance therapy.
Up until very recently, no non-peptidyl, reversible, highly selective MOR
antagonists have been discovered. Based on molecular modeling, use of the
message-address concept, and in vitro pharmacological screening studies, the
objective of this study is to identify a compound has the mentioned features.
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1.9 MOR mutational studies
Since MOR mediates most of the physiological responses of clinically relevant
opioids, it was important to investigate the MOR structure and compare to other
opioid receptors to understand the structural basis of the function and regulation of
the MOR. All opioid receptors share around 60-70% similarity at the level of amino
acids, particularly in the transmembrane and intracellular regions, which correlates
highly with the common signaling mechanism among opioid receptor types. On the
other hand, the N-terminus, C-terminus, and second and third extracellular loops
exhibit most of the dissimilarity, which is consistent with the different affinities for
different opioid ligands, as well as some differences in receptor regulation by
intracellular proteins that interact with the C-terminus (Pasternak & Pan, 2013). Sitedirected mutagenesis studies revealed several amino acid residues required for
ligand binding and selectivity. Results from these studies illustrate the complexity of
ligand-receptor interaction due to the high degree of reliance on several conserved
amino acids. While more than 20 amino acids can affect ligand binding affinity, two
seem to play an important role in ligand binding affinity, His297 and Asp114. A D114N
receptor mutation decreased the binding affinity for DAMGO and morphine, while the
affinities of partial agonists, nalbuphine and buprenorphine, and antagonists,
naloxone and diprenorphine, were not influenced (Bot et al., 1998; Xu et al., 1999).
In comparison, the mutation H297N decreased partial agonists’ affinities for MOR,
but not DAMGO and morphine (Bot et al., 1998).
As for MOR selectivity, three amino acids have been identified as key
residues, Asp147, Asn150, Trp318. The significant role of Trp318, located in EL3, has
been illustrated by two studies. W318K/L mutation produced a reduction of binding
affinity for MOR ligands, like DAMGO, fentanyl, and naltrexone. Also, Trp318 serves
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as a key residue for binding MOR-selective ligands and excluding DOR-selective
ligands. This was depicted when the W318L mutant produced a notable increase in
the affinity of DPDPE, a DOR selective ligand. The W318L mutant was intentionally
designed to mimck the DOR, as leucine occupies the analogous position of
tryptophan in DOR (Bonner et al., 2000). Additionally, the other study confirmed the
role of Trp318 by constructing a W318A mutant that resulted in undetectable affinity
levels for MOR ligands (Xu et al., 1999).
Asn150 is a conserved residue that is located in TM7 in all opioid receptors.
Asn150 mutation increased the affinity for MOR agonists, but not antagonists, when
substituted with alanine (N150A) (A Mansour et al., 1997). Also, the conserved
aspartate residue located in TM3 (Asp147) was shown to play a role in binding of
MOR agonists only. However, another study excluded the role of Asp147 as a
requirement for high affinity binding (Surratt et al., 1994).
Since Trp318 is only found in the MOR and its mutation affected the binding
affinity of MOR antagonists, manipulation of Trp318 and NTX docking studies were
conducted to explore the interaction of substituted antagonists with MOR to assist in
the design of novel MOR-selective antagonist compounds.
NTX is considered a universal template for designing opioid receptor
antagonists. Naltrindole (NTI), norbinaltrophimine (norBNI), and guanidinenaltrindole
(GNTI) are successfully modified derivatives of NTX. A molecular modeling study of
the opioid receptors using NTX as the probe showed an aromatic binding pocket was
formed between C(6) of NTX and Trp318 of MOR, but not in DOR or KOR, thus
suggesting a critical role of Trp318 in MOR selectivity. This could serve as an
alternative address binding domain. Based on this hypothesis, 16 compounds were
synthesized by introducing a heteroaromatic moiety onto the 6-position of NTX,
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either in a or b configuration. An amide group was used to link the side chain of each
moiety to the morphinan skeleton; thus, these compounds are naltrexamine
derivatives. Out of the 16 compounds, two were identified as promising leads, NAQ
and 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β(4′pyridylcarboxamido)morphinan (NAP). Both had high affinity for the MOR (Ki=
0.55 and 0.37 nM, respectively). The Ki ratio of NAQ for DOR/MOR was 241 and for
KOR/MOR was 48, while the NAP Ki ratio for DOR/MOR was 747 and for KOR/MOR
was 163. Further molecular modeling study verified that NAP and NAQ recognized
the alternative address domain in the MOR (Li et al., 2009). Recently, this Trp318
residue was mutated to alanine (W318A) and expressed in CHO cells to test the
binding affinity of NTX, NAP, and NAQ. This study revealed that the affinity for NTX
was not affected by the mutation, whereas the affinities for NAQ and NAP were
dramatically reduced to undetectable values (Table 1) (Zaidi et al., 2013).
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Table 1. Binding of ligands to site directed mutated MORs (Zaidi et al., 2013).
Compounds

Wild type MOR (nM) ± SEM
IC50

Ki

W318A MOR (nM) ± SEM
IC50

NTX

3.90 ± 2.96

1.85 ± 1.41

NAP

2.29 ± 0.15

1.09 ± 0.07

>1000

NDa

NAQ

5.42 ± 0.70

2.57 ± 0.33

>1000

NDa

a,

10.35 ± 1.64

Ki
4.91 ± 0.78

not detectable.
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1.10 Hypothesis
Based on the previously discussed premise regarding the potential role of
W318 in MOR selectivity and through application of the message-address concept
for designing compounds, we hypothesize that introducing an indole ring at position
6 of naltrexamine will lead to enhanced MOR affinity relative to the DOR or KOR
possibly through the formation of Pi-Pi stacking with the W318 residue in the MOR.
Therefore, 18 compounds were synthesized using naltrexone as the parent
compound and naltrexamine as an intermediate parent. These compounds are
substituted either in the a or b configuration. The indole rings are attached to the
morphinan skeleton at the 5-member ring, 6-member ring, or a substituted mutiple
carbon linker at position 3 on indole rings (Figure 6).
This study will determine the affinity of the synthesized compounds by
radioligand competition binding at mMOR, mDOR, and mKOR that are
heterologously and stably expressed in CHO cells, hence the potential confound of
the existence of more than one opioid receptor will be avoided in this system. Next,
the efficacy for MOR-mediated G-protein activation will be evaluated using
[35S]GTPgS binding in mMOR-CHO cells. Furthermore, the efficacy of the most
MOR-selective lead compounds will be compared to the efficacy of known opioid
compounds with low efficacy at the MOR in both mMOR-CHO cells and mouse
thalamus, the brain region expressing the highest MOR density relative to other
opioid receptor types. We hypothesize that 6-indole-substituted naltrexamine
analogs that are highly MOR-selective will retain low efficacy for MOR activation.
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6a-naltrexamine

6b-naltrexamine

R groups

Figure 6. The indole analogues of 6a-naltrexamine (dashed line) and 6b-naltexamine
(solid line) were synthesized by Samuel Obeng in Dr. Zhang’s lab.
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Chapter 2.

Experimental Procedures

2.1. Chemical synthesis
The novel compounds were synthesized by Samuel Obeng in Dr. Zhang’s lab.
2.2 Materials
2.2.1 Chemicals
[3H]naloxone ([3H]NLX) (70 Ci/mmol), ([3H]dieprnorphine ([3H]DIP) (25.1 Ci/mmol),
NTX, SNC80, U50,488, [D-Ala2 ,N-MePhe4, Gly5-ol] enkephalin (DAMGO),
Guanosine-5'-O'- (g-thio)-triphosphate (GTPgS), [35S]GTPgS, GDP, Trizma base
(Tris), Adenine deaminase (ADase), hydrochloric acid (HCl), magnesium chloride,
sodium chloride (NaCl), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic
acid (EGTA), and Econo-1 scintillation fluid.

2.2.2 Cell culture
Stable CHO cell lines with heterologous expression of mMOR, mDOR, mKOR
were used. Cells obtained from liquid nitrogen storage were thawed. Before
transferring the cells into a culture dish (55 cm2) containing 9 ml of pre-warmed
complete growth medium (1:1 mixture of 500 ml of DMEM/F12 media including Fetal
Bovine Serum (FBS), penicillin/streptomycin, and G418), 1 ml of the same growth
medium was slowly added into the cryovial to accelerate warming. Next,
resuspended cells were incubated at 37 oC with CO2 and 95 % humidity for 24 hours
to allow the formation of a cell monolayer, after which the media was replaced with
fresh culture media. mMOR-CHO cells were cultured in 1:1 mixture of 500 ml of
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DMEM/F12 media including 10% FBS, 1% penicillin/streptomycin, and 0.5% G418.
The same culture media was used for mDOR and mKOR except that 5% FBS was
used. The cells were split after a period of time in which they were allowed to grow
until 85-95% confluency was attained. As for splitting cells, first the old media was
aspirated and the cells were rinsed with 5 ml phosphate buffered saline (PBS), then
3 ml trypsin was added and the cells were placed in the incubator for 5 min or until
all cells are completely detached. After aspirating trypsin, cells were suspended in 10
ml culture media and portion of the cells was transferred to another culture dish
containing 10 ml media. The cells were placed back in the incubator. The media
would be replaced with a fresh one periodically. For the next splitting, the surface
area of culture dish was changed from 55 cm2 to 152 cm2 to increase the number of
growing cells. The cells then would be split from one dish to eight or ten dishes.
When the cells were confluent, they were harvested. First, the media was removed
and each culture dish was rinsed with 5 ml PBS and another 5 ml PBS was added to
each dish. Cells were then scrapped off the dishes using a Teflon cell scraper and
then transferred into a 50 ml centrifuge tube, which was then centrifuged at 1,000 x g
for 10 minutes. The supernatant was decanted and the cells were suspended in
membrane buffer (50 mM Tris, 3 mM MgCl2, and 1 mM EGTA, PH 7.4). The cells
were then homogenized using a Polytron and centrifuged at 5,0000 x g for 10
minutes at 4°C. The supernatant was then decanted and the cell pellet was
homogenized to re-suspend in membrane buffer. Membrane protein levels were
determined by the method of Bradford (Hammond & Kruger, 1988). The membranes
were then aliquoted at 3 mg membrane protein per cryovial and stored at -80 oC until
use.

38

2.3 Membrane preparation
Membranes prepared from MOR-, DOR-, and KOR-CHO cells were recovered
in the same manner, as follows. Cells were obtained from -80oC storage, thawed and
then transferred into a centrifuge tube containing 4 mL membrane buffer.
Membranes were homogenized and the suspension was then centrifuged at 50,000
x g for 10 minutes at 4°C. The supernatant was decanted and the pellet was resuspended in 4 mL binding assay buffer (50mM Tris-HCl, 3 mM MgCl2, and 0.2 mM
EGTA; pH 7.7) and homogenized, The Bradford assay was used to measure the
protein concentration in the membrane preparations to be used in the assay. For
[35S]GTPgS binding assays, MOR-CHO membranes were prepared as described
above; however, GTPgS assay buffer was used instead (50 mM Tris-HCl, 3mM
MgCl2, 0.2 mM EGTA, and 100 mM NaCl; pH 7.7). Thalamus from adult male ICR
mouse (obtained pre-dissected from -80°C storage and provided by Dr. Laura SimSelley) was also prepared in the same way to be used in [35S]GTPgS binding assays.

2.4 Radioligand binding assay
For the determination of affinity and selectivity of the compounds under
investigation, radioligand binding assays were used. [3H]NLX was used to label MOR
and [3H]DIP was used to label both DOR and KOR. Prior to performance of
competition binding assays with the novel compounds, radioligand saturation binding
assays were conducted to determine KD and Bmax values of the radiolabeled ligands
in each cell line. Varying concentrations of [3H]NLX or [3H]DIP were incubated in
binding assay buffer with 30 µg of MOR-, DOR-, or KOR-CHO cell membrane
protein in the absence and presence of 5 µM of naltrexone, SNC80 or U50,488,
respectively, to determine specific binding at each receptor.
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To determine the affinity of the novel compounds at MOR, 25-30 µg mMORCHO membranes were incubated with 1-2 nM [3H]NLX and varying concentrations of
each test compound in a 500 µL total volume for 90 minutes at 30oC. Naltrexone (5
µM) was used to determine non-specific binding. Total specific binding was
measured in the absence of competitor compounds. The incubation was terminated
by rapid filtration through Whatman GF/B glass fiber filters, followed by three washes
with 1 mL per wash of cold 50 mM Tris-HCl buffer (pH 7.4). The filters containing
bound radioligand were transferred to scintillation vials, which then were filled with 4
mL Econo-1 scintillation fluid. Bound radioactivity was measured by liquid scintillation
spectrophotometry at 45% efficiency for 3H.
The affinity of the novel compounds for DOR and KOR was determined
according to the same procedure described above, with the following exceptions.
Membranes (25-30 µg protein) were obtained from DOR- or KOR-CHO cells,
respectively. The radioligand was [3H]DIP, 1.26 nM for DOR and 0.95 nM for KOR.
Non-specific binding was determined in the presence of 5 µM SNC80 or U50,488 for
DOR and KOR, respectively. All KOR binding assays were conducted by Samuel
Obeng.
All competition binding assays were conducted in triplicate and replicated at
least three times. All saturation binding assays were conducted in duplicate and
replicated at least twice. All binding assay reagents were kept on ice during sample
preparation until transfer to sample tubes for incubation at 30°C.

2.5 [35S] GTPgS functional assay
To determine the functional activity of the novel compounds at the primary
target receptor, MOR, the ligand-stimulated [35S]GTPgS binding assay was
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performed in membranes from the same MOR-CHO cell line in which MOR binding
affinity was determined. The efficacy of the novel compounds was measured at MOR
relative to a maximally effective concentration (3 µM) of the full agonist DAMGO.
Membranes (10 µg protein) were incubated in GTPgS assay buffer with 0.1 nM [35S]
GTPgS, 20 µM GDP, and varying concentrations of each novel compound in a 500
mL total volume for 90 minutes at 30 oC. Unlabeled GTPgS (20 µM) was used to
detect non-specific binding. Basal binding was measured in the absence of any MOR
ligand. The incubation was terminated by rapid filtration under vacuum through
Whatman GF/B glass fiber filters, followed by three rinses with 1 mL per rinse of cold
50 mM Tris-HCl buffer (pH 7.4). The filters containing bound radioligand were
transferred to scintillation vials, which then were filled with 4 mL Econo-1 scintillation
fluid. Bound radioactivity was measured by liquid scintillation spectrophotometry at
90% efficiency for 35S.
[35S]GTPgS binding assays in mouse thalamus were conducted following the
same procedure except that 8 µg membrane protein, 10 µM DAMGO, and 30 µM
GDP were used, and the incubation period was 2 hours.
All first-tier screen [35S]GTPgS binding assays were conducted in duplicate
and repeated at least three times. Second-tier screens were also conducted in MORCHO cells and mouse thalamus to compare the lead novel ligands to known opioid
ligands, and these assays were conducted in duplicate and replicated at least four
times. All assay reagents were kept on ice during sample preparation until transfer to
sample tubes for incubation at 30°C.
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2.6 Data analysis
Results were reported as mean ± SEM. Radioligand binding curves and
concentration-effect curves were fit by nonlinear regression analysis with Prism 6.0
software (GraphPad Software, San Diego, CA) to obtain KD, Bmax, IC50, Hill slope,
Emax, and EC50 values. The raw data were transformed to the appropriate format for
analysis using Microsoft Excel software and then applied to Prism. For competition
analysis, four-parameter fit was used with the total specific binding (top) constrained
to 100% and complete competition (bottom) constrained to 0% to determine the IC50
and Hill slope values. For [35S]GTPgS binding concentration-effect curves, fourparameter fit was used with the minimum (bottom) constrained to 0% to determine
the Emax, EC50 and Hill slope values. For saturation analysis of specific binding,
three-parameter fit was used with the minimum constrained to 0 to determine the
radioligand KD, Bmax and Hill slope values.
The Cheng-Prusoff equation was used to calculate Ki values [Ki= IC50 /
(1+(L*/KD*))] where L* is the concentration of the radioligand and KD* is the
equilibrium dissociation constant of the radioligand. The efficacy of the tested
compounds was calculated as relative to net DAMGO-stimulated [35S]GTPgS
binding, which is defined as [Emax as % Maximal Stimulation = (net stimulation by
ligand/net stimulation by 3 µM DAMGO) x 100%] in MOR-CHO cells or [Emax as %
Maximal Stimulation = (net stimulation by ligand/net stimulation by 10 µM DAMGO) x
100%] in mouse thalamus.
One-way ANOVA with the post-hoc Newman-Keuls test was conducted to
determine significant differences in Emax values between the lead compounds and
known opioid ligands in MOR-CHO cells and mouse thalamus. Student’s t-tests were
conducted to determine whether the Hill slope values of the novel compounds were
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significantly different from 1. The significance cut-off (a) was set at 0.05 in all
statistical tests.
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Chapter. 3 Results
3.1 Affinity of the indole derivatives of 6a and 6b-naltrexamine for MOR
Radioligand binding assays were performed to determine the binding affinity
of the indole derivatives of naltrexamine for the mouse MOR-CHO cells using
mMOR-CHO cell membranes. Methodological details for these assays are provided
in Chapter.2.

3.1.1 Affinity of the indole derivatives of 6a-naltrexamine for MOR
Compared to known compounds, like NTX and NAQ, the MOR binding affinity
of the novel 6-substituted indole analogs did not differ substantially. For the purpose
of deciphering structure-activity relationships among the novel ligands, the
compounds were divided into three groups according to the position of attachment of
the indole ring substituent to the morphinan skeleton. From the results obrained, it
was noticed that the position where the indole rings are attached to the morphinan
skeleton did not affect the binding affinity greatly. Altough there was variation in the
affinity within each group among the a configuration analogues, the magnitude of the
difference was relatively small. For example, compound 106 (with substitution at
position 7 of the indole ring) had the highest affinity among the a analogues, which
was only 3.3-fold higher than compound 092 (with substitution at position 5 of the
indole ring) (Figure 7 and Table 2). Moreover, it was observed that the MOR binding
affinity increased with increasing length of the alkyl chain at position 3 of the indole
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ring. Interestingly, all compounds had Hill slope values greater than 1. Nevertheless,
it should be noted that compound 099 (with no linker) in which the indole ring is
directly attached to the carbonyl group had almost the same Ki value as compound
102 with three a carbon-length spacer, indicating a biphasic relationship of spacer
length and binding affinity.
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Figure 7. Inhibition of [3H]naloxone binding to MOR by the indole derivatives of 6analtrexamine. A) compounds 090 and 099 (with substitutions at positions 2 and 3 of
the indole ring). B) compounds 095, 092, 093, and 106 (with substitutions at
positions 4, 5, 6, and 7 of the indole ring). C) compounds 091, 101, and 102 (with
increasing the length of the alky chain with one, two, and three carbon atoms,
respectively, at position 3 of the indole ring). Data are presented as mean values ±
SEM from at least three experiments. The concentration of [3H]naloxone in MOR
binding assays was 1.51 ± 0.06 nM and the total binding in the absence of the
competitor was 1.72 ± 0.07 pmol/mg.
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Table 2. MOR Ki(nM) and Hill slope values for the indole derivatives of 6analtrexamine.

substitution
position
Substitutions at a
5-member ring

Substitutions at a

Ki (nM) ± SEM

Hill slope± SEM

VZMN090

0.36 ± 0.03

-1.42 ± 0.18

VZMN099

0.28 ± 0.04

-1.54 ± 0.08*

VZMN095

0.26 ± 0.04

-1.29 ± 0.07*

VZMN092

0.76 ± 0.11

-1.61 ± 0.1*

VZMN093

0.43 ± 0.05

-1.24 ± 0.12

VZMN106

0.23 ± 0.01

-1.37 ± 0.08*

VZMN091

0.74 ± 0.12

-1.06 ± 0.05

VZMN101

0.43 ± 0.04

-1.59 ± 0.16*

VZMN102

0.29 ± 0.03

-1.85 ± 0.12*

Code

R

6-member ring

Alkyl chain linker
at position 3 of a
5-member ring

Table 2. MOR Ki(nM) and Hill slope values for the indole derivatives of 6analtrexamine. The novel compounds are divided into three groups according to the
position of substitution in the indole ring. Data are presented as mean values ± SEM
from at least three experiments. *, Hill coefficient was p < 0.05 different from one as
determined by Student’s t-test.
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3.1.2 Affinity of the indole derivatives of 6b-naltrexamine for MOR
Unlike a analogues, b analogues had less variation in their binding affinities
with 2.6-fold difference between the compound with the highest (compound 104) and
lowest affinity (compound 094). The Ki values of the b analogues were smaller than
those of a analogues. Most Ki values were either in 0.2 nM range or less (Table 3
and Figure 8). However, the binding affinity was close to the affinity of NTX (0.33
nM), indicating that the b configuration did not affect the affinity substantially. As with
their respective a analogues, several b analogues also had Hill slope values of
greater than 1. Overall, the binding affinity of 6a and 6b-naltrexamine indole
derivatives showed considerably high affinity for MOR.
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Figure 8. Inhibition of [3H] naloxone binding to MOR by the indole derivatives of 6bnaltrexamine. A) compounds 096 and 109 (with substitutions at positions 2 and 3 of
the indole ring). B) compounds 098, 097, 094, and 107 (with substitutions at
positions 4, 5, 6, and 7 of the indole ring). C) compounds 100, 104, and 105 (with
increasing the length of the alky chain with one, two, and three carbon atoms,
respectively, at position 3 of the indole ring). Data are presented as mean values ±
SEM from at least three experiments.
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Table 3. MOR Ki(nM) and Hill slope values for the indole derivatives of 6bnaltrexamine.
substitution

Ki (nM) ± SEM

Hill slope± SEM

VZMN096

0.28 ± 0.03

-2.2 ± 0.31#

VZMN109

0.19 ± 0.01

-1.93 ± 0.07#

VZMN098

0.23 ± 0.03

-1.58 ± 0.09#

VZMN097

0.28 ± 0.03

-2.17 ± 0.64

VZMN094

0.42 ± 0.03

-1.59 ± 0.07#

VZMN107

0.18 ± 0.01

-1.8 ± 0.05#

VZMN100

0.24 ± 0.03

-1.58 ± 0.08#

VZMN104

0.16 ± 0.01

-1.65 ± 0.13#

VZMN105

0.20 ± 0.02

-1.93 ± 0.2#

Code

R

position
Substitutions at b
5-member ring

Substitutions at b
6-member ring

Alkyl chain linker
at position 3 of b 5member ring

Table 3. MOR Ki(nM) and Hill slope values for the indole derivatives of 6bnaltrexamine. The novel compounds are divided into three groups according to the
position of substitution in the indole ring. Data are presented as mean values ± SEM
from at least three experiments. #, Hill coefficient was p < 0.05 different from one as
determined by Student’s t-test.
.
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3.2 Affinity of the indole derivatives of 6a and 6b-naltrexamine for KOR

3.2.1 Affinity of the indole derivatives of 6a-naltrexamine for KOR
From the results obtained, it can be seen that the position of the substitution
on the indole ring did not affect the binding affinity for KOR substantially. Among the
indole analogues of 6a-naltrexamine, compound 092 had the least affinity for KOR
with Ki value of 3.44 nM whilst compound 102 had the highest affinity for KOR with
subnanomolar Ki value. The other a indoles had Ki values ranged from 1 to around
1.5 nM (Table 4). Increasing the length of the linker between the indole ring and
morphinan skeleton led to higher affinity (compounds 091, 101, and 102). Compared
to NTX, the affinity of a analogues for KOR were either slightly lower or higher.
However, none of the indole analogues of 6a-naltrexamine had lower affinity for
KOR than NAQ.

3.2.2 Affinity of the indole derivatives of 6b-naltrexamine for KOR
Interestingly, all the indole analogues of 6b-naltrexamine produced very high
affinity for KOR. Unlike the indole analogues of 6a-naltrexamine, the range of Ki
values of the indole analogues of 6b-naltrexamine did not exceed 1 nM except for
compound 098, which had ~ 2nM (Table 5). Elongating the length of the linker did
not have a pattern of either increasing, as in a analogues, or decreasing the binding
affinity.
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3.3 Affinity of the indole derivatives of 6a and 6b-naltrexamine for DOR
3.3.1 Affinity of the indole derivatives of 6a-naltrexamine for DOR
Generally, the affinity of the indole derivatives of 6a-naltrexamine for DOR is
lower than for KOR. From the results obtained, it could be assumed that the position
of the substitution had a greater impact on the affinity of the indole derivatives of 6analtrexamine for DOR than for KOR. Compounds 102 and 092 had the highest and
lowest affinity for DOR, Ki = 6.73 nM and 26.7 nM, respectively. The range of Ki
values for other compounds was between 10-25 nM (Table 4). The alkyl chain length
that links the indole ring to the morphinan skeleton did not have an effect on the
affinity when it is elongated by one more carbon atom.

3.3.2 Affinity of the indole derivatives of 6b-naltrexamine for DOR
The position of the substitution on the indole ring on the b configuration
produced greater variation on the affinity within the indole derivatives of 6bnaltrexamine. Two compounds had the lowest affinity with Ki of 50 nM or above, 098
and 104. Compound 096 had the highest affinity, Ki = 1.54 nM. The indole
derivatives of 6b-naltrexamine had a wider range of Ki values than the a indoles,
which was from 1.54 to 77.28 nM (Table 5). Increasing the length of the linker
between the indole ring and morphinan skeleton did not have a pattern in either
enhancing or decreasing the affinity.

52

3.4 Selectivity for MOR over KOR and DOR of indole derivatives 6a and 6bnaltrexamine
Neither the substitutions nor the configuration greatly enhanced the selectivity
for MOR over KOR (Table 4 and 5). Compound 106 in the a configuration and
compound 098 in the b configuration had the highest selectivities with 7.4 and 8.7,
respectively, affinity ratio for MOR over KOR. It is worth mentioning that both of
these compounds were linked to the 6-position carbon of the morphinan skeleton via
the 6-member ring of the indole group. However, the position of the substitution in
the indole ring was different, with compound 106 linked at the 7 position and
compound 098 at the 4 position, which are opposite (para) to each other on the 6member ring. In general, the a indole analogues had better selectivity for MOR over
KOR than the b indole analogues.
In contrast to selectivity over KOR, the selectivity for MOR over DOR was
significantly enhanced by the substitution and the configuration (Table 4 and 5).
Among a analogues, compound 106 had the best selectivity, 60-fold selective for
MOR over DOR. It was noticed that the b analogues generally had higher selectivity
for MOR over DOR than a analogues. Compound 104 was 461-fold selective for
MOR over DOR. Compound 098 had also good selectivity for MOR over DOR, at
212-fold selective. It can be seen from the selectivity ratios of these novel
compounds that compound 106, in the a configuration, and compound 098, in the b
configuration, had good selectivity for MOR over both KOR and DOR.
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Table 4. Ki values of indole derivatives of 6a-naltexamine at KOR and DOR and
selectivity summary.
Ki (nM) ± SEM

Selectivity
Ratio

compound

R

µ

k

d

k/µ

d/µ

NTXa

0.33 ± 0.02 1.44 ± 0.11 143.5 ± 13.7

4.4

435

NAQa

1.11 ± 0.07

169.9 ± 15.0

12

146

13.3 ± 1.1

VZMN090

0.36 ± 0.03 0.93 ± 0.13

14.2 ± 2.8

2.5

39.2

VZMN099

0.28 ± 0.04 0.98 ± 0.13

10.5 ± 2.9

3.4

37.0

VZMN095

0.26 ± 0.04 1.49 ± 0.35

9.3 ± 2.8

5.6

35.1

VZMN092

0.76 ± 0.11 3.44 ± 0.99

26.7 ± 7.7

4.5

35.0

VZMN093

0.43 ± 0.05 1.63 ± 0.28

12.8 ± 3.4

3.8

29.4

VZMN106

0.23 ± 0.01 1.69 ± 0.35

13.7 ± 1.4

7.4

60

VZMN091

0.74 ± 0.12 3.13 ± 0.45

9.2 ± 2.7

4.2

12.2

VZMN101

0.43 ± 0.04 1.36 ± 0.18

25.1 ± 6.8

3.1

57.3

54

VZMN102

0.29 ± 0.03 0.15 ± 0.03

6.73 ± 0.40

0.5

23.0

Table 4. Ki values of indole derivatives of 6a-naltexamine at KOR and DOR and
selectivity summary for MOR over both KOR and DOR. Data are presented as mean
values ± SEM from at least three experiments. The concentration of [3H]
dipernorphine in KOR binding assays was 0.95 ± 0.07 nM and the total binding in the
absence of the competitor was 0.43 ± 0.01 Pmol/mg. The concentration of [3H]
dipernorphine in DOR binding assays was 1.26 ± 0.17 nM and the total binding in the
absence of the competitor was 1.0 ± 0.06Pmol/mg. aNTX and NAQ Ki values (Yuan
et al., 2015)
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Table 5. Ki values of indole derivatives of 6b-naltexamine at KOR and DOR and
selectivity summary
Ki (nM) ± SEM

Selectivity
Ratio

compounds

R

µ

k

d

k/µ

d/µ

VZMN096

0.28 ± 0.03

0.18 ± 0.002

1.54 ± 0.47

0.6

5.4

VZMN109

0.19 ± 0.01

0.16 ± 0.01

7.17 ± 1.2

0.83

37.3

VZMN098

0.23 ± 0.03

1.94 ± 0.30

49.8 ± 12.7

8.2

212

VZMN097

0.28 ± 0.03

0.51 ± 0.04

17.7 ± 4.8

1.8

63

VZMN094

0.42 ± 0.03

0.17 ± 0.01

6.2 ± 0.8

0.7

26

VZMN107

0.18 ± 0.01

0.52 ± 0.09

30.4 ± 9.5

2.8

162

VZMN100

0.24 ± 0.03

0.95 ± 0.11

37.0 ± 1.2

3.9

153.5

VZMN104

0.16 ± 0.01

0.39 ± 0.05

77.1 ± 28.3

2.3

461.6

56

VZMN105

0.20 ± 0.02

0.18 ± 0.04

25.3 ± 4.3

0.83 124.5

Table 5. Ki values of indole derivatives of 6b-naltexamine at KOR and DOR and
selectivity summary for MOR over both KOR and DOR. Data are presented as mean
values ± SEM from at least three experiments
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3.3 Efficacy of the indole derivatives of 6a and 6b-naltrexamine at mMOR-CHO
To determine the efficacy of the novel indole 6-substituted naltrexamine
analogs for MOR-mediated G-protein activation, concentration-effect curves for
ligand-stimulated [35S]GTPgS binding were examined in mMOR-CHO cell
membranes. The stimulation by each compound was normalized to that of a
maximally effective concentration (3 µM) of the full MOR agonist DAMGO, so that
the Emax values derived from the curve fits represent the relative efficacy of each
compound (Emax of DAMGO = 100%).

3.3.1 Efficacy of the 6a-naltrexamine indole derivatives at mMOR-CHO
The results show that the position of substitutions on the indole rings did not
substantially affect potency or efficacy. All a analogues had low to moderate efficacy
to activate the MOR (Figure 9 and Table 6). Compound 106 (substitution at position
7) had the lowest efficacy, with a relative Emax of 19% (of DAMGO), while compound
099 was the most potent, an EC50 value of 0.1 nM. Increasing the length of the alkyl
chain at position 3 led to enhancement of both potency and efficacy, and compound
102 with a three carbon linker was the most efficacious. However, compound 099
with no spacer between the indole and the morphinan skeleton was more potent
than the compounds that had additional carbon spacers. All the a analogues
produced Hill slope values that were not significantly different from 1.
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3.3.2 Efficacy of the 6b-naltrexamine indole derivatives at mMOR-CHO
In contrast to their respective a analogues, the b analogues had greater
variation in efficacy and potency as a function of position of substitution. Emax values
ranged from as low as 17% of DAMGO to as high as 92% of DAMGO (Figure 10 and
Table 7). EC50 values also varied from sub-nanomolar to 14nM. Compounds 097
and 098 were lowest in efficacy with Emax values of 17% and 22% of DAMGO,
respectively. However, compounds 096, 109, and 094 were the most efficacious,
with Emax values of 92%, 79%, and 72% of DAMGO, respectively. The other
compounds had low to moderate efficacy, ranging from approximately 26% to 55%.
Most compounds had Hill slope that were not different from 1.
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Figure 9. Concentration-effect curves of indole derivatives of 6a-naltrexamine for the
stimulation of [35S]GTPgS binding in mMOR-CHO cells. A) compounds 090 and 099
(with substitutions at positions 2 and 3 of the indole ring). B) compounds 095, 092,
093, and 106 (with substitutions at positions 4, 5, 6, and 7 of the indole ring). C)
compounds 091, 101, and 102 (with increasing the length of the alky chain with one,
two, and three carbon atoms, respectively, at position 3 of the indole ring). Data are
presented as mean values ± SEM from at least three experiments. Net agonist
stimulated [35S]GTPgS binding was 173.37 ± 15.63 fmol/mg and the basal binding in
the absence of an agonist was 48.63 ± 2.95 fmol/mg.
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Table 6. Emax (%DAMGO), EC50, and Hill slope values for indole derivatives of 6analtrexmine.
Compound

Emax
(% DAMGO)

Log EC50

Hill slope

VZMN090

36.91 ± 2.40

-8.40 ± 0.24

1.63 ± 0.49

(6.75 nM)
VZMN099

33.33 ± 3.51

-9.02 ± 0.06

0.89 ± 0.11

(0.10 nM)
VZMN095

28.90 ± 0.95

-8.52 ± 0.29

1.28 ± 0.50

(4.99 nM)
VZMN092

32.24 ± 1.25

-8.81 ± 0.02

1.50 ± 0.38

(1.54 nM)
VZMN093

26.62 ± 0.66

-8.26 ± 0.09

1.69 ± 0.53

(6.05 nM)
VZMN106

19.11 ± 3.31

-8.67 ± 0.27

1.92 ± 0.30

(3.85 nM)
VZMN091

34.13 ± 0.97

-8.31 ± 0.02

0.90 ± 0.04

(4.75 nM)
VZMN101

41.55 ± 6.14

-8.68 ± 0.04

0.87 ± 0.10

(2.09 nM)
VZMN102

54.89 ± 6.34

-9.14 ± 0.09

1.57 ± 0.40

(1.89 nM)
Table 6. Emax (%DAMGO), EC50, and Hill slope values for indole derivatives of 6analtrexmine. Emax (%DAMGO), EC50, and Hill slope values for indole derivatives of
6a-naltrexmaine derived from Concentration-effect curves for the stimulation of
[35S]GTPgS binding in mMOR-CHO cells. Data are presented as mean values ±
SEM from at least three experiments.

61

Figure 10. Concentration-effect curves of indole derivatives of 6b-naltrexamine for
the stimulation of [35S]GTPgS binding in mMOR-CHO cells. A) compounds 096 and
109 (with substitutions at positions 2 and 3 of the indole ring). B) compounds 098,
097, 094, and 107 (with substitutions at positions 4, 5, 6, and 7 of the indole ring). C)
compounds 100, 104, and 105 (with increasing the length of the alky chain with one,
two, and three carbon atoms, respectively, at position 3 of the indole ring). Data are
presented as mean values ± SEM from at least three experiments.
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Table 7. Emax (%DAMGO), EC50, and Hill slope values for indole derivatives of 6bnaltrexamine
Compound

Emax
(% DAMGO)

Log EC50

Hill slope

VZMN096

92.42 ± 2.81

-9.69 ± 0.02

1.54 ± 0.22

(0.21 nM)
VZMN109

79.48 ± 7.40

-9.75 ± 0.18

0.65 ± 0.09

(0.22 nM)
VZMN098

16.22 ± 1.40

-8.22 ± 0.33

1.62 ± 0.62

(8.15 nM)
VZMN097

22.32 ± 3.50

-8.64 ± 0.19

6.01 ± 4.40

(2.97 nM)
VZMN094

71.79 ± 4.37

-9.72 ± 0.04

0.93 ± 0.17

(0.19 nM)
VZMN107

37.94 ± 5.85

-9.10 ± 0.11

0.82 ± 0.07

(1.92 nM)
VZMN100

48.27 ± 4.45

-9.04 ± 0.24

0.91 ± 0.34

(1.44 nM)
VZMN104

45.08 ± 5.18

-9.29 ± 0.16

0.68 ± 0.03°

(1.73 nM)
VZMN105

36.29 ± 4.11

-8.99 ± 0.07

0.85 ± 0.12

(1.04 nM)
Emax (%DAMGO), EC50, and Hill slope values for indole derivatives of 6bnaltrexmaine derived from Concentration-effect curves for the stimulation of
[35S]GTPgS binding in mMOR-CHO cells. Data are presented as mean values ±
SEM from at least three experiments. °, Hill coefficient was p < 0.05 different from
one as determined by Student’s t-test.
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3.4 Correlation of Ki values with EC50 values at MOR
Analysis was conducted in order to determine the correlation of the affinity
with the potency at MOR of the novel ligands. Results showed that the Ki values did
not correlate with EC50 values (r2 = 0.034, p = 0.465; Figure 11). Further analysis of
the a or b analogs, each as a separate group, also showed no correlation between
Ki values and EC50 values (r2 = 0.004 and 0.008, p = 0.815 and 877, respectively).
Although this finding was somewhat surprising, multiple factors could potentially
account for such results. For example, different assay conditions in receptor binding
versus functional assays might play a role in these results. This will be discussed
further in Chapter 4.

Figure 11. Correlation of Ki values with EC50 values in mMOR-CHO cells.

3.5 Efficacy comparison to known compounds (NAQ and nalbuphine) in
mMOR-CHO
Based on the initial screen for efficacy of the indole analogues, compounds
098 and 106 had the lowest efficacy. To determine how these compounds compared
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with known opioid compounds with low efficacy for MOR activation, a direct
comparison was conducted in mMOR-CHO cells using the [35S]GTPgS binding
assay. As in the initial functional screen, all compounds were compared with the full
MOR agonist DAMGO. However, one parameter was changed from the initial
screen. Three concentration points per log unit were used in this study, as opposed
to two concentrations per log unit in the initial screen, in order to obtain a more
accurate assessment of curve-fit parameters with these low efficacy compounds.
The results (Figure 12 and Table 8) showed that compounds 098 and 106 appeared
to have slightly lower efficacy than the low efficacy partial agonist nalbuphine, which
is available clinically. They also had slightly lower apparent efficacy than the MORselective low efficacy partial agonist NAQ. As expected, NTX was the least
efficacious with less than 10% of maximum DAMGO stimulation, which is consistent
with its accepted action as a MOR antagonist. Statistical analysis, however, did not
find any significant differences in Emax values between compounds 98, 106,
nalbuphine and NAQ, although all four of these ligands had significantly higher
efficacy than NTX and lower efficacy than DAMGO. The full MOR agonist DAMGO
produced maximum activation of MOR. In this particular assay, both compounds 106
and 098 had Hill slopes were not significantly different from 1. Under these
experimental conditions, both compounds 098 and 106 had relative efficacy values
that were essentially the same as nalbuphine and NAQ (Figure 13).
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Figure 12. Concentration-effect curves of compounds 106, 098, NAQ, nalbuphine,
NTX, and DAMGO for the stimulation of [35S]GTPgS binding in mMOR-CHO cells
from side-by-side comparison experiments. Data are presented as mean values ±
SEM from at least three experiments. Net agonist stimulated [35S]GTPgS binding
was 167.58 ± 9.01 fmol/mg and the basal binding in the absence of an agonist was
32.54 ± 1.77 fmol/mg.
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Table 8. Emax (%DAMGO), EC50, and Hill slope values for compounds VZMN098,
VZMN106, nalbuphine, NAQ, NX, and DAMGO from side-by-side
Compound

Emax
(% DAMGO)

EC50 (Log M)

Hill slope

VZMN098

23.18 ± 2.05

-9.15 ± 0.24

0.76 ± 0.10

(0.84 nM)
VZMN106

25.46 ± 1.58

-9.01 ± 0.11

1.05 ± 0.11

(1.12 nM)
nalbuphine

33.83 ± 3.54

-7.92 ± 0.04

0.96 ± 0.07

(12.1 nM)
NAQ

29.53 ± 2.85

-8.64 ± 0.1

1.18 ± 0.01

(2.47 nM)
NTX

9.73 ± 0.72

-9.29 ± 0.11

1.38 ± 0.45

(0.60 nM)
DAMGO

100.00 ± 1.45

-7.94 ± 0.08

1.07 ± 0.08

(12.42 nM)

Emax (%DAMGO), EC50, and Hill slope values for derived from Concentration-effect
curves of compounds VZMN098, VZMN106, nalbuphine, NAQ, NX, and DAMGO for
the stimulation of [35S]GTPgS binding in mMOR-CHO cells. Data are presented as
mean values ± SEM from at least three experiments.
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Figure 13. Comparison of ligand Emax values in mMOR-CHO cells. Values are mean
Emax ± SEM derived from the curve fits shown in Figure 11. Values that do not
contain any of the same letter designations are p < 0.05 different from each other as
determined by ANOVA with post-hoc Newman-Keuls test.
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3.6 Efficacy comparison to NAQ in mouse thalamus
To compare the relative efficacy of these novel lead 6-indole substituted
compounds with NAQ under more native conditions, [35S]GTPgS binding was
conducted in membranes from mouse thalamus. Thalamus was chosen because it is
the highest MOR-expressing region of the brain, and contains only very low levels of
KOR and DOR. Although DAMGO produced robust stimulation of [35S]GTPgS
binding in the thalamus, compounds 098 and 106 produced very low stimulation
similar to NAQ. It was difficult to obtain an accurate Emax or EC50 values due to the
very low level of stimulation produced by 098, 106, and NAQ. The Emax value for
compound 106 was only 11% of DAMGO, compared to 16% for NAQ, and the
concentration-effects curves for compound 098 could not be unambiguously fit
(Table 9 and Figure 14). Under these experimental conditions, compound 106 had a
relative efficacy value that was essentially the same as NAQ (Figure 15) and a Hill
slope that was not significantly different from 1.
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Figure 14. Concentration-effect curves of compounds 106, 098, NAQ, and DAMGO
for the stimulation of [35S]GTPgS binding in membranes that were prepared from
mouse thalamus from side-by-side comparison experiments. Data are presented as
mean values ± SEM from four experiments in which four mice thalami were used.
Net agonist stimulated [35S]GTPgS binding was 221.13 ± 5.73 fmol/mg and the basal
binding in the absence of an agonist was 125.19 ± 4.13 fmol/mg.
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Table 9. Emax (%DAMGO), EC50, and Hill slope values for compounds VZMN098,
VZMN106, NAQ, and DAMGO in mouse thalamus.

Compound

Emax
(% DAMGO)

EC50 (Log M)

Hill slope

VZMN098

NDa

NDa

NDa

VZMN106

11.21 ± 0.96

-7.62 ± 0.23

1.36 ± 0.20

(37 nM)
NAQ

16.35 ± 4.36

-7.47 ± 0.13

3.07 ± 1.38

(42 nM)
DAMGO

106.0 ± 1.83

-6.67 ± 0.06

0.75 ± 0.06

(214 nM)
Emax (%DAMGO), EC50, and Hill slope values for derived from Concentration-effect
curves of compounds VZMN098, VZMN106, and DAMGO for the stimulation of
[35S]GTPgS binding in mouse thalamus. “a” denotes that those values were not
detectable. Data are presented as mean values ± SEM four experiments in which
four mice thalami were used.
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Figure 15. Comparison of ligand Emax values in mouse thalamus. Values are mean
Emax ± SEM derived from the curve fits shown in Figure 13. Values that do not
contain any of the same letter designations are p < 0.05 different from each other as
determined by ANOVA with post-hoc Newman-Keuls test.
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Chapter 4. Discussion
The identification of nonpeptidyl, highly selective, reversible MOR selective
antagonists is essential for the treatment of opioid dependence/addiction. The
reason that blocking MOR could help in treating opioid addiction/dependence is that
MOR mediates not only the analgesic effects of clinically prescribed opioids, but also
the abuse-related effects of prescribed opioids and heroin (Kieffer, 1999). Also, a
MOR selective antagonist could serve as a tool in MOR structural characterization
and opioid agonists functional studies. As previously mentioned in the introduction,
so far, the current MOR antagonists have disadvantages that limit either their clinical
or research applications. Previous molecular modeling and docking studies of NAP
and NAQ in all opioid receptor types revealed an alternative address domain in the
MOR. The W318 residue, which is located at the border of TM7 and EL3 of the
MOR, is recognized by NAP and NAQ through the formation of a Pi-Pi stacking
interaction (Zaidi et al., 2013). Based on this modeling result, 18 indole analogues of
6a and 6b-nlatrexamine were designed and synthesized based on the massageaddress concept. This study hypothesized that introducing the indole ring at position
6 of the morphinan skeleton would yield compounds that prefer a Pi- Pi-stacking
interaction with the W318 residue in MOR. These novel compounds, should they
provide the required high selectivity and low efficacy at the MOR, could be
developed and formulated for use in the treatment of opioid dependence/addiction.
First, receptor binding assays were conducted to determine the affinity of the
novel compounds for MOR and the selectivity for MOR over KOR and DOR. In this
assay, the novel compounds compete with labeled naloxone for binding to MOR, and
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labeled diprenorphine for binding to KOR and DOR. CHO cells that stably and
heterologously express MOR, KOR, or DOR were used to determine the relative
affinities and therefore selectivity for MOR compared to the other two opioid
receptors. Such cell systems eliminate the chance of binding of the radioligand to
another opioid receptor and provide more precise results because it allows
measurement of competition of the novel ligands to a single receptor type.
The MOR binding data revealed that all of the indole analogues of 6a and 6bnaltrexamine had very high affinity with mostly subnanomolar Ki values (Tables 2
and 4). This means that the position of the substitution on the indole ring did not
have a substantial effect on the affinity for MOR. Compound 106 (the 7-substituted
indole analogue of 6a-naltrexamine) had the highest affinity among a analogues,
with a Ki value of 0.23 nM, while compound 092 (the 5-substituted indole analogue of
6a-naltrexamine) had the least affinity, with a Ki value of 0.76 nM (Figure 7 and
Table 2). It was noticed that increasing the length of the linker at position 3 on the
indole ring by one or two additional carbons enhanced the binding affinity
(compounds 091, 101, and 102 in the a configuration). Nonetheless, it should be
noted that there is some sort of biphasic relationship regarding the distance between
the indole ring and the morphinan skeleton. Compound 099 is directly attached to
the carbonyl group and had almost the same Ki value as compound 102 with the
three-carbon linker. This suggests that there is no single distance between the
substituent and the morphinan skeleton that is optimal for MOR affinity. Further
docking study could demonstrate how directly attaching the substituent or varying
the length of the linker affects the mode of interaction of the novel compounds with
MOR. For example, it might facilitate interaction with the W318 residue of MOR by
the indole ring. As for the indole analogues of 6b-naltrexamine, compound 104 (with
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the two-carbon linker at position 3 of the indole ring) had a Ki value of 0.16 nM which
was the best affinity and 2.6-fold greater than the worst affinity, which was obtained
with compound 094 (the 6 substituted indole analogue) (Figure 8 and Table 3).
Although the a and b configurations showed high binding affinity for MOR, the extent
of the affinity variation within each configuration differed. It was observed that the
indole analogues of 6a-naltrexamine had somewhat greater variation in their Ki
values than did the indole analogues of 6b-naltrexamine. The Ki values for the indole
analogues of 6a-naltrexamine ranged from 0.23 to 0.76 nM, while the Ki values of
the indole analogues of 6b-naltrexamine ranged from 0.16 to 0.42 nM. Generally, the
indole analogues of 6b-naltrexamine had better affinity for MOR than their respective
a analogs. On the other hand, when compared to the affinity of NAQ and NAP for
the MOR, the introduction of the indole ring to the morphinan skeleton did not
substantially alter the binding affinity. The Ki values of NAQ, NAP, and NTX lie within
the obtained Ki range for the novel compounds (1.11 nM, 0.37 nM, and 0.33 nM,
respectively), when taking experimental variance into account. Interestingly, most
compounds had Hill slope values of more than one. Only three compounds in the a
indole analogues had Hill slopes that were not significantly different from 1 (090,
093, and 091). For the b indole analogues, all compounds exhibited Hill slopes that
were significantly different from 1 except for compound 097. This could indicate
positive cooperativity in binding to the MOR. One explanation for the high Hill slope
could be that the indole ring of the compound recognizes W318 in MOR first and that
facilitates the docking of the whole compound into the binding pocket. However,
further docking study of compounds with high Hill slope will be needed to illustrate
the most likely mode of binding of these indole analogues.
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KOR binding data revealed that indole analogues of 6a and 6b naltrexamine
showed high binding affinity for the KOR. Among the indole analogues of 6analtrexamine, compounds 102 and 092 had the lowest and highest affinity (with Ki=
0.15 and 3.44 nM, respectively) (Table 4). Intriguingly, all of the indole analogues of
6b naltrexamine exhibited subnanomolar Ki values except compound 098, which was
had a Ki value of ~ 2 nM (Table 5). Considering the Ki ratio of KOR/MOR, two
compounds were identified with the greatest selectivity ratio: compound 106 (the 7
substituted of 6a-naltrexamine) with 7.4-fold selectivity for MOR over KOR and
compound 098 (the 4 substituted of 6b-naltrexamine) with 8.2-fold selectivity for
MOR over KOR (Table 4 and 5). Interestingly, increasing the length of the linker at
position 3 of the indole ring in the a configuration, but not the b configuration, led to
enhancement of the affinity for both MOR and KOR. Thus, the relatively low
selectivity ratio of compounds in this series could be attributed to the similarity of
effect of linker length on the interaction of these novel compounds with MOR and
KOR. A previous docking study of NTX showed that the carbon 6 on the carbonyl
group was pointing toward an aromatic binding pocket in MOR and there was also
an aromatic binding pocket that was formed while interacting with KOR (Li et al.,
2009). A more recent docking study of NAP and NAQ in MOR and KOR revealed
that both compounds formed aromatic interaction, Pi-Pi stacking, and possibly
hydrogen bond (Zaidi et al., 2013). In order to confirm this speculation with the indole
analogues of 6a and 6b-naltrexamine, further docking study is required. When
comparing NTX or NAQ, the selectivity ratios of the novel compounds for MOR over
KOR was not enhanced substantially. The most selective compounds, 106 and 098,
had a higher selectivity ratio than NTX, 7.4 and 8.2 versus 4.4, but had lower
selectivity ratios than NAQ, with a selectivity ratio of 12. Generally, the introduction of
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the indole substitution at position 6 of naltrexamine in either the a or b configuration
did not enhance the selectivity for MOR over KOR from the previously known 6substituted naltrexamine analogs that have already been published by the Zhang
and Selley laboratories (Yuan et al., 2011, 2015).
In contrast to KOR binding data, DOR binding data showed a greater variation
in the binding affinity among the indole analogues of either 6a or 6b-naltrexamine.
Among the a analogues, compounds 102 and 092 produced the least and highest Ki
values, 6.73 and 26.7 nM (Table 4). In contrast to the respective a analogues, the
indole analogues of 6b-naltrexamine displayed a larger variation in DOR binding
affinities. The Ki values ranged from 1.54 to 77.1 nM, which were exhibited by
compounds 096 and 104 (Table 5). Given the low affinity of compound 104 for DOR,
it showed the highest selectivity ratio for MOR over DOR among the indole
analogues of 6a and 6b-naltrexamine, at approximately 460-fold selectivity for MOR
over DOR. Among the indole analogues of 6a-naltrexamine, only compound 106 had
a selectivity ratio larger than 50-fold for MOR over DOR, while compound 091 had
the lowest, at 60- and 12-fold selectivity for MOR over DOR, respectively (Table 4).
Unlike the binding affinity for MOR and KOR, increasing the length of the linker at
position 3 of the indole ring in the a configuration did not produce the same effect for
DOR. Intriguingly, most indole derivatives in the b configuration of 6-naltrexamine
demonstrated high selectivity ratios for MOR over DOR. Six out of 9 compounds had
greater than 50-fold selectivity, and 5 of these had more than 100-fold-selectivity for
MOR over DOR (Table 5). Compared to NTX and NAQ, some compounds had better
selectivity for MOR over DOR while others had lower selectivity ratios. In general,
the indole analogues of 6a and 6b-naltrexamine displayed better selectivity for MOR
over DOR than for MOR over KOR. A potential explanation for the difference in the
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interaction of these ligands with DOR versus KOR was reveled by molecular
modeling. A docking study of NTX in DOR showed no formation of an aromatic
binding locus to which the C6 carbonyl group pointed in DOR (Li et al., 2009).
Docking study of NAQ and NAP in DOR showed no formation of hydrogen bond as
was the case in MOR or KOR (Zaidi et al., 2013). Considering the selectivity for
MOR over KOR and DOR, compound 106 (the 7-substituted indole analogue of 6analtrexamine) and compound 098 (the 4-substituted indole analogue of 6bnaltrexamine) had the best overall selectivity ratios.
From our binding results, it was determined that introducing the indole ring in
the hypothesized address domain produced higher affinity for MOR relative to KOR
in 13 out of 18 compounds; 8 of these compounds had the indole substituent in the a
configuration and 5 in the b. However, only 2 of the 18 compounds had better
selectivity than NTX for MOR over KOR. Our prediction that the indole ring might
form more stable aromatic interaction (e.g., Pi-Pi stacking) with the W318 residue in
MOR than the corresponding Tyr residue (Y312) in KOR was based on the reduced
affinity of NAQ and NAP for MOR with mutated W318 (Table 1). However, the Y312
residue in KOR might form a sufficiently stable aromatic interaction with the indole
ring. It was shown that the pyridine ring of NAP and isoquinoline rings of NAQ can
form aromatic interaction with Y312 in KOR, but to lesser extent than W318 in MOR
(Zaidi et al., 2013). Another reason that why our novel ligands have low selectivity for
MOR over KOR might be due to the formation of hydrogen bonding with different
amino acid residues in both MOR and KOR. This was demonstrated with both NAQ
and NAP docking studies (Zaidi et al., 2013). On the other hand, our results showed
that the selectivity of our novel ligands, particularly the b analogues, for MOR over
DOR was much better than KOR. In fact, all 18 of the novel indole-containing ligands
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were more selective for MOR than DOR. One reason could be that the indole
analogs might not form strong aromatic interaction in DOR or lack the hydrogen
bond formation as in the case of NAP and NAQ (Zaidi et al., 2013). Nonetheless,
only one compound of the indole series (compound 104) had greater selectivity for
MOR over DOR than naltrexone. Therefore, we can conclude that although these
novel ligands generally possessed reasonable selectivity for MOR over KOR or
DOR, consistent with the hypothesized role of the address domain, the improvement
in selectivity over NTX was modest. Nonetheless, because MOR selectivity over
KOR is challenging in morphinan ligands, the fact that two ligands showed
somewhat improved selectivity for MOR versus KOR compared to naltrexone is
encouraging. However, our results also indicate that the indole substitution is unlikely
to yield greater selectivity than substitution with a pyridine or isoquinoline ring, as in
NAP and NAQ, respectively.
.
Another important feature of a desired compound is to have no or low efficacy
at MOR, because this is the main receptor that mediates biological responses of
clinically relevant and abused opioids, and was the primary target for which these
series of ligands were designed to be selective. The indole analogues of 6a and 6bnaltrexamine were therefore tested in the MOR-CHO cells using the [35S]GTPgS
binding functional assay to evaluate the pharmacodynamic efficacy of the novel
compounds. The results were analyzed in such a way as to normalize the stimulation
produced by each compound to that obtained by the full MOR agonist DAMGO,
which provided a measurement of relative efficacy. The results obtained for the
indole analogues of 6a-naltrexamine showed that all compounds produced low to
moderate efficacy. Compound 106 had the lowest efficacy, with an Emax value »
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19%, of DAMGO, while compound 102 had the highest Emax value with 54% (Figure
9 and Table 6). As for the potency, the EC50 values ranged from approximately 1.5 to
6.5 nM, expect for compound 099, which was the most potent with an EC50 value of
0.1 nM. There was a corresponding increase in the Emax and potency of compounds
091, 101, and 102 with the increasing the length of the alkyl chain. However, as
observed previously from MOR binding results, there could be a biphasic relationship
regarding the distance between the indole ring and the morphinan skeleton that
affects the potency. Compound 099 was more potent than those with the alkyl chain
spacers. This is consistent with the binding affinity of these compounds at MOR,
which could be further explored in the future using iterative SAR and modeling study.
None of the a analogues had a Hill slope significantly different from 1 in these
functional assays.
Unlike the a indole analogues, the indole analogues of 6b-naltrexamine
displayed a greater variation in the Emax values, revealing compounds of both very
high efficacy and very low efficacy. Compound 096 was the most efficacious with an
Emax value of 92% of DAMGO, while compounds 097 and 098 were the least
efficacious with Emax values of 22% and 17%, respectively (Figure 10 and Table 7).
However, the potency range was tighter in the indole analogues of 6b-naltrexamine
than the range of their respective a analogs. With the exception of 098, which was
the least potent with an EC50 value of ~14 nM, the EC50 values ranged from 0.2 nM
to 3 nM. It was also observed that elongating the length of the alkyl chain of the
carbon spacer at position 3 did not produce the same pattern of potency increase as
in the a analogues. Only compound 104 had a Hill slope that was significantly
different from 1.
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Surprisingly, compounds 109, and 094 demonstrated high efficacy, with Emax
values that were very close to that of DAMGO, and compound 096 was already
known to have high efficacy. The chemical modifications that were applied to the
novel compounds were expected to alter only the binding affinity based on previous
SAR studies and the message-address concept, in which only the address domain
was modified by introducing the indole ring without changing the components that
are related to the efficacy. However, it is clear from the data that these modifications
also affected the efficacy, producing compounds with a range of efficacies for Gprotein activation ranging from low efficacy partial agonists to nearly full agonists
despite the fact that these novel indole-containing ligands were based on parent
compounds that are MOR antagonists. In fact, three of the 18 novel compounds in
the b configuration and one in the a had relative efficacies for G-protein activation
that were >50% of the full agonist, DAMGO. On the other hand, only one compound
in the a configuration and two in the b had relative efficacies <25% of DAMGO, and
all other compounds were in the moderate efficacy partial agonist range (~25-50% of
DAMGO). Therefore, it can be concluded that modifying this hypothetical address
domain also affected the functional activity of these ligands, although at present we
have no accurate means to predict this structure-function relationship. Apparently,
ligand interactions with GPCRs are complex, and it is difficult to predict the functional
outcomes for the applied modification by the message address concept. The
introduction of the indole ring to the hypothetical address domain might change the
mode of ligand-receptor interaction in such way that leads to activation of the
receptor. One speculation is that maybe the W318 residue in the MOR plays a role in
both affinity and efficacy. Of note, both of the most optimally MOR-selective of these
indole-containing ligands, compounds 98 and 102, also retained low efficacy similar
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to NAQ. Therefore, further molecular modeling studies are required to interpret the
SAR related to the role of 6-position substituent interactions with specific amino acid
residues in the determination of ligand efficacy at the MOR.
As shown in Figure 11, the novel ligands produced Ki values that do not
correlate with EC50 values as expected. One explanation could be the different assay
conditions in the receptor binding assay versus the functional assay. The presence
of GDP and NaCl in the [35S]GTPgS assay can affect the affinity of opioid agonists.
As previously discussed in Chapter 1.6.2, both GDP and NaCl facilitate a receptor
conformation that does not have high affinity for agonists (Selley et al., 2000; Selley
et al., 1997). This is manifested in compound 098, which had a Ki value less than 0.5
nM and EC50 value of approximately 8 nM. Another procedural factor that could have
differentially affected the Ki and EC50 measurements is the selection of ligand
concentration range for each assay. For the Ki determination, multiple ligand
concentrations were selected that produced between 5 and 95% competition, with
the maximum and minimum radioligand binding constrained to 100 and 0%,
respectively. This was done to optimize the affinity determination. In contrast, the
most important value obtained from the [35S]GTPgS binding assays was the relative
efficacy. Therefore, a broad concentration range was selected such that several data
points would fall on the maximum plateau of the curve so the maximum effect could
be determined experimentally, with only the minimum effect constrained (to 0%).
Therefore, the Ki value determinations were likely to be more accurate than the EC50
values. Indeed, a subset of ligands (compounds 92, 93, 97, 98, 102 and 106) were
re-assayed for stimulation of [35S]GTPgS binding in mMOR-CHO cells using a
narrower ligand concentration range, with 3 concentrations per log unit (data not
shown). A correlation analysis between the EC50 values determined by this method
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with the previously determined Ki values was then conducted for these compounds,
and the correlation was highly significant (r2 = 0.937, p = 0.0015). Therefore, future
experiments comparing the Ki and EC50 values of all the novel 6-indole analogs
under identical assay conditions, including ligand concentrations, would likely show
the expected correlation between binding affinity and functional potency.
So far, when considering the binding affinity for MOR, selectivity for MOR over
KOR and DOR, and efficacy at MOR, the introduction of indole ring at postiton 6 of a
and b-naltrexamine revealed that 2 out of 18 novel compounds had the desired
pharmacodynamic profile. Compounds 106 (the 7 substituted indole analogue of 6analtrexamine) and 098 (the 4 substituted of 6b-naltrexamine) were the most selective
for MOR over KOR and DOR, and demonstrated the least efficacy at MOR. To
further characterize the identified compounds, a side by side comparison was
conducted with compounds known to have low efficacy at MOR.
The comparison was conducted in mMOR-CHO cells against NAQ,
nalbuphine, NTX, and DAMGO. It can be seen from the results (Table 8 and Figure
12) that compounds 106 and 098 produced slightly lower apparent Emax values than
NAQ and nalbuphine, but were not significantly different from NAQ (Figure 13). As
expected, NTX showed the lowest Emax that was statistically different from the low
efficacy partial agonists and DAMGO (Figure 13). Comparing all low efficacy
compounds to DAMGO, there was a significant difference in Emax values.
Compounds 098 and 106 had Hill slope values that were not different from 1.
To avoid sole reliance on data from transfected cell lines, the lead compounds
were tested in membranes prepared from mouse thalamus, which expresses mostly
the MOR with very low densities of other opioid receptor types. [35S]GTPgS binding
assays were conducted to evaluate the abilities of compounds 106 and 098 to
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stimulate MOR-mediated G-protein activation in comparison with NAQ and DAMGO.
It was difficult to obtain accurate Emax and EC50 values for 098 because of the very
low level of stimulation produced. Compound 098 acted essentially as an antagonist
in thalamus. Compound 106 and NAQ showed approximately 11% and 16% Emax
values, respectively, indicating that both ligands acted as partial agonists of very low
relative efficacy (there was no significant Emax difference between 106 and NAQ).
Consistent with the Hill slope values obtained from mMOR-CHO cells, compound
106 produced a Hill slope that was not significantly different from 1. These results
are consistent with previous studies that demonstrated the concept that a low
efficacy partial agonist in a system expressing high receptor density can act as a
pure antagonist in a system with a low receptor density. For instance, levallorphan
acted as a low partial agonist in mMOR-CHO cells, but as a pure antagonist in rat
thalamus (Selley et al., 1997). Also, NAQ acted as pure antagonist when it inhibited
DAMGO-stimulated [35S]GTPgS binding in MOR-CHO cells engineered to express
MOR at low density (~0.4 pmol/mg), which further supported the concept that a low
efficacy partial agonist can act as an antagonist in a system with low receptor density
(Yuan et al., 2011). So far, compounds 106 and 098 showed promising data to serve
as new lead compounds in continuing investigations with the purpose of developing
novel MOR-selective antagonists as potential treatment drugs for opioid
dependence/addiction.
To determine whether these newly identified leads are superior to the
previously synthesized compounds, NAQ and NAP, further pharmacological
characterizations are required. First, the intrinsic efficacy of the lead compounds at
KOR and DOR would play a major role in considering their potential superiority over
other compounds. As mentioned in Chapter 1.8 one of the side effects of NTX that
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causes dysphoria is, possibly, partial agonism at KOR and antagonism at DOR. It
has been illustrated that NAQ and NAP have low and moderate efficacy at KOR,
respectively (Yuan et al., 2011). The antagonism, or very low efficacy, property at
KOR is a desirable feature because activation of the KOR causes dysphoria
(Lalanne et al., 2014). Therefore, further [35S]GTPgS functional assays will be
required to test the efficacy of our leads at KOR and DOR.
Moreover, the competitive property of an antagonist is essential. An
irreversible (noncompetitive) antagonist is not as clinically safe because it does not
dissociate from the receptor, leading to a reduction in the available number of
receptors until synthesis of new receptors occurs. Also, in pharmacological studies
an irreversible antagonist is not favored because it cannot be washed out from the
binding locus to revive the receptors. Yet, in some studies an irreversible antagonist
can be a valuable tool. NAP and NAQ are known to be competitive antagonists
because they produced a right-shift in the concentration-effect curve of DAMGO
(Yuan et al., 2011). For that reason, compounds 106 and 098 will need to be tested
for competitive antagonism of MOR in the future.
Furthermore, the pharmacokinetic properties will need to be evaluated. In
order for the lead compounds to be used for opioid dependence/addiction, they need
to have the ability to penetrate into the CNS. NAQ is known to cross the blood-brain
barrier (BBB), whereas NAP does not (Yuan et al., 2011). Whether similar results will
be obtained with the lead indole analogues will determine their potential for
application in targeting the MOR either peripherally or centrally.
Interestingly, NAQ did not exhibit precipitation of withdrawal symptoms like
the known opioid antagonists, NTX and naloxone (Yuan et al., 2011). One of the
main side effects of NTX is precipitating withdrawal symptoms if it is co-administered
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during long-term administration of an opioid agonist. Hence, it might be worthwhile to
test the withdrawal-precipitating activity of these novel leads because the benefit of
not precipitating withdrawal symptoms could strengthen the potential for use of these
antagonists after minimal weaning of addicts from the opioid agonist.
Eventually, following more extensive in vitro tests, such as inhibition of
adenylyl cyclase and b-arrestin recruitment, of the lead compounds, in vivo tests will
ultimately provide measures of effectiveness in the intact animal. In vivo evaluation
of NAQ revealed that it acted as a potent antagonist and did not produce any
significant agonist activity in acute antinociceptive agonistic and antagonistic effects
in the tail immersion test in mice even at high doses (Yuan et al., 2011). Thus, in vivo
tests would determine whether the indole leads would behave like NAQ or not.

To summarize, the introduction of an indole ring at position 6 of a and bnaltrexamine revealed 2 out of 18 novel compounds that showed promising affinity,
selectivity, and efficacy data to continue investigation. However, further
pharmacological characterizations are required to determine whether these indole
analogues possess any advantages over the previously synthesized compounds,
NAQ and NAP. Furthermore, feeding molecular and docking studies with the data
obtained in this study could produce interesting results from which to interpret the
SAR in terms of precise molecular interactions with the opioid receptors.

86

Reference List

87

Reference List

Al-Hasani, R., & Bruchas, M. R. (2011). Molecular Mechanisms of Opioid Receptordependent Signaling and Behavior. Anesthesiology, 1.
https://doi.org/10.1097/ALN.0b013e318238bba6
Ballantyne, J. C., & LaForge, K. S. (2007). Opioid dependence and addiction during
opioid treatment of chronic pain. Pain, 129(3), 235–255.
https://doi.org/10.1016/j.pain.2007.03.028
Bardo, M. T. (1998). Neuropharmacological Mechanisms of Drug Reward: Beyond
Dopamine in the Nucleus Accumbens. Critical Reviews in Neurobiology, 12(1–
2), 37–68. https://doi.org/10.1615/CritRevNeurobiol.v12.i1-2.30
Bart, G. (2012). Maintenance medication for opiate addiction: the foundation of
recovery. Journal of Addictive Diseases, 31(3), 207–25.
https://doi.org/10.1080/10550887.2012.694598
Bidlack, J. M. (2014). Mixed Kappa/Mu Partial Opioid Agonists as Potential
Treatments for Cocaine Dependence. In Advances in pharmacology (San
Diego, Calif.) (Vol. 69, pp. 387–418). https://doi.org/10.1016/B978-0-12-4201187.00010-X
Blake, A. D., Bot, G., Freeman, J. C., & Reisine, T. (1997). Differential opioid agonist
regulation of the mouse mu opioid receptor. The Journal of Biological Chemistry

88

, 272(2), 782–90. https://doi.org/10.1074/JBC.272.2.782
Bonner, G., Meng, F., & Akil, H. (2000). Selectivity of μ-opioid receptor determined
by interfacial residues near third extracellular loop. European Journal of
Pharmacology, 403(1–2), 37–44. https://doi.org/10.1016/S0014-2999(00)005781
Booth, M. (1999). Opium: a history. St. Martin’s Griffin. Retrieved from
https://books.google.com/books?hl=en&lr=&id=HXGzAAAAQBAJ&oi=fnd&pg=P
R1&dq=Opium:+A+history&ots=HQbvNSyqQg&sig=xjfzNiszyz79BqktimQPyrC9
WEg#v=onepage&q=Opium%3A A history&f=false
Bot, G., Blake, A. D., Li, S., & Reisine, T. (1998). Mutagenesis of a Single Amino
Acid in the Rat u-Opioid Receptor Discriminates Ligand Binding. Journal of
Neurochemistry Lippincott—Raven Publishers Philadelphia J. Neurochem, 70,
358–365. Retrieved from file:///Users/Abadi779/Downloads/Bot_et_al-1998Journal_of_Neurochemistry.pdf
Breivogel, C. S., Selley, D. E., & Childers, S. R. (1998). Cannabinoid receptor
agonist efficacy for stimulating [35S]GTP??S binding to rat cerebellar
membranes correlates with agonist-induced decreases in GDP affinity. Journal
of Biological Chemistry. https://doi.org/10.1074/jbc.273.27.16865
Brownstein, M. J. (1993). A brief history of opiates, opioid peptides, and opioid
receptors. Proc. Natl. Acad. Sci., 90(June), 5391–5393.
https://doi.org/10.1073/pnas.90.12.5391
Chavkin, C., & Goldstein, A. (1981). Demonstration of a specific dynorphin receptor
in guinea pig ileum myenteric plexus. Nature, 291(5816), 591–593.
https://doi.org/10.1038/291591a0
Chavkin, C., & Martinez, D. (2015). Kappa Antagonist JDTic in Phase 1 Clinical Trial.

89

Neuropsychopharmacology: Official Publication of the American College of
Neuropsychopharmacology, 40(9), 2057–8. https://doi.org/10.1038/npp.2015.74
Chen, Y., Mestek, A., Liu, J., Hurley, J. A., & Yu, L. (1993). Molecular cloning and
functional expression of a mu-opioid receptor from rat brain. Molecular
Pharmacology, 44(1). Retrieved from
http://molpharm.aspetjournals.org.proxy.library.vcu.edu/content/44/1/8
Clinical Gate. (2015). Drugs to Control Pain. iKnowledge, 1(1), 1–5. Retrieved from
https://clinicalgate.com/drugs-to-control-pain/
Comb, M., Seeburg, P. H., Adelman, J., Eiden, L., & Herbert, E. (1982). Primary
structure of the human Met- and Leu-enkephalin precursor and its mRNA.
Nature, 295(5851), 663–666. https://doi.org/10.1038/295663a0
Costa, T., Klinz, F. J., Vachon, L., & Herz, A. (1988). Opioid receptors are coupled
tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell
membranes. Molecular Pharmacology, 34(6). Retrieved from
http://molpharm.aspetjournals.org.proxy.library.vcu.edu/content/34/6/744
Côté, T. E., Izenwasser, S., & Weems, H. B. (1993). Naltrexone-induced
upregulation of mu opioid receptors on 7315c cell and brain membranes:
enhancement of opioid efficacy in inhibiting adenylyl cyclase. Journal of
Pharmacology and Experimental Therapeutics, 267(1). Retrieved from
http://jpet.aspetjournals.org/content/267/1/238
Creese, I., & Snyder, S. H. (1975). Receptor Binding and Pharmacolgical Activity of
Opiates in the Guinea-Pig Intestine. J. Pharmacol. Exp. Ther., 194(1), 205–219.
Dang, V. C., & Christie, M. J. (2012). Mechanisms of rapid opioid receptor
desensitization, resensitization and tolerance in brain neurons. British Journal of
Pharmacology, 165(6), 1704–16. https://doi.org/10.1111/j.1476-

90

5381.2011.01482.x
David, V., & Cazala, P. (2000). Anatomical and pharmacological specificity of the
rewarding effect elicited by microinjections of morphine into the nucleus
accumbens of mice. Psychopharmacology, 150(1), 24–34. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/10867973
David, V., Matifas, A., Gavello-Baudy, S., Decorte, L., Kieffer, B. L., & Cazala, P.
(2008). Brain Regional Fos Expression Elicited by the Activation of?- but not?Opioid Receptors of the Ventral Tegmental Area: Evidence for an Implication of
the Ventral Thalamus in Opiate Reward. Neuropsychopharmacology, 33(7),
1746–1759. https://doi.org/10.1038/sj.npp.1301529
Doverty, M., White, J. M., Somogyi, A. A., Bochner, F., Ali, R., & Ling, W. (2001).
Hyperalgesic responses in methadone maintenance patients. Pain, 90(1), 91–
96. https://doi.org/10.1016/S0304-3959(00)00391-2
Evans, C. J., Keith, D. E., Morrison, H., Magendzo, K., & Edwards, R. H. (1992).
Cloning of a Delta Opioid Receptor by Functional Expression. Source: Science,
New Series, 258(5090), 1952–1955. Retrieved from
http://www.jstor.org/stable/2880480
Fan, P., Jiang, Z., Diamond, I., & Yao, L. (2009). Up-regulation of AGS3 during
morphine withdrawal promotes cAMP superactivation via adenylyl cyclase 5 and
7 in rat nucleus accumbens/striatal neurons. Molecular Pharmacology, 76(3),
526–33. https://doi.org/10.1124/mol.109.057802
Feng, Y., He, X., Yang, Y., Chao, D., Lazarus, L. H., & Xia, Y. (2012). Current
research on opioid receptor function. Current Drug Targets, 13(2), 230–46.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22204322
Fields, H. L., & Margolis, E. B. (2015). Understanding opioid reward. Trends in

91

Neurosciences, 38(4), 217–225. https://doi.org/10.1016/j.tins.2015.01.002
Flores, L. R., Hernandez, M. C., & Bayer, B. M. (1994). Acute immunosuppressive
effects of morphine: lack of involvement of pituitary and adrenal factors. Journal
of Pharmacology and Experimental Therapeutics, 268(3). Retrieved from
http://jpet.aspetjournals.org.proxy.library.vcu.edu/content/268/3/1129
Florio, V. A., & Sternweis, P. C. (1989). Mechanisms of muscarinic receptor action
on Go in reconstituted phospholipid vesicles. The Journal of Biological
Chemistry, 264(7), 3909–15. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/2492992
Froehlich, J. C. (1997). Opioid peptides. Alcohol Health and Research World, 21(2),
132–6. Retrieved from https://pubs.niaaa.nih.gov/publications/arh21-2/132.pdf
Ghelardini, C., Di Cesare Mannelli, L., & Bianchi, E. (2015). The pharmacological
basis of opioids. Clinical Cases in Mineral and Bone Metabolism: The Official
Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal
Diseases, 12(3), 219–21. https://doi.org/10.11138/ccmbm/2015.12.3.219
Goldstein, A., Tachibana, S., Lowney, L. I., Hunkapiller, M., & Hood, L. (1979).
Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proceedings of the
National Academy of Sciences of the United States of America, 76(12), 6666–
70. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/230519
Hamm, H. E. (1998). The Many Faces of G Protein Signaling*. The Journal of
Biological Chemistry. Retrieved from
http://www.jbc.org/content/273/2/669.full.pdf
Hammond, J. B., & Kruger, N. J. (1988). The bradford method for protein
quantitation. Methods in Molecular Biology (Clifton, N.J.), 3, 25–32.
https://doi.org/10.1385/0-89603-126-8:25

92

Hanner, M., Moebius, F. F., Flandorfer, A., Knaus, H. G., Striessnig, J., Kempner, E.,
& Glossmann, H. (1996). Purification, molecular cloning, and expression of the
mammalian sigma1-binding site. Proceedings of the National Academy of
Sciences of the United States of America, 93(15), 8072–7. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/8755605
Harrison, C., & Traynor, J. R. (2003). The [35S]GTPgammaS binding assay:
approaches and applications in pharmacology. Life Sciences, 74(4), 489–508.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14609727
Harrison, R. S., Ruiz-Go?mez, G., Hill, T. A., Chow, S. Y., Shepherd, N. E., Lohman,
R.-J., … Fairlie, D. P. (2010). Novel Helix-Constrained Nociceptin Derivatives
Are Potent Agonists and Antagonists of ERK Phosphorylation and Thermal
Analgesia in Mice. Journal of Medicinal Chemistry, 53(23), 8400–8408.
https://doi.org/10.1021/jm101139f
Hildebrandt, J. D. (1997). Role of subunit diversity in signaling by heterotrimeric G
proteins. Biochemical Pharmacology, 54(3), 325–339.
https://doi.org/10.1016/S0006-2952(97)00269-4
Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A., & Morris,
H. R. (1975). Identification of two related pentapeptides from the brain with
potent opiate agonist activity. Nature, 258(5536), 577–579.
https://doi.org/10.1038/258577a0
Jaffe, J., & Martin, W. (1990). Narcotic analgesics and antagonists. In The
Pharmacological Basis of Therapeutics (pp. 485–521). New York: Macmillan.
Keen, M. (1991). Testing models of agonism for G protein-coupled receptors. Trends
in Pharmacological Sciences, 12(10), 371–4. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/1662422

93

Kekuda, R., Prasad, P. D., Fei, Y.-J., Leibach, F. H., & Ganapathy, V. (1996).
Cloning and Functional Expression of the Human Type 1 Sigma Receptor
(hSigmaR1). Biochemical and Biophysical Research Communications, 229(2),
553–558. https://doi.org/10.1006/bbrc.1996.1842
Kieffer, B. L. (1999). Opioids: first lessons from knockout mice. Trends in
Pharmacological Sciences, 20(1), 19–26. https://doi.org/10.1016/S01656147(98)01279-6
Knoll, A. T., Muschamp, J. W., Sillivan, S. E., Ferguson, D., Dietz, D. M., Meloni, E.
G., … Jr. (2011). Kappa opioid receptor signaling in the basolateral amygdala
regulates conditioned fear and anxiety in rats. Biological Psychiatry, 70(5), 425–
33. https://doi.org/10.1016/j.biopsych.2011.03.017
Koob, G. F. (1992). Drugs of abuse: anatomy, pharmacology and function of reward
pathways. Trends in Pharmacological Sciences, 13, 177–184.
https://doi.org/10.1016/0165-6147(92)90060-J
Koski, G., & Klee, W. A. (1981). Opiates inhibit adenylate cyclase by stimulating GTP
hydrolysis. Biochemistry, 78(7), 4185–4189. Retrieved from
http://www.pnas.org/content/78/7/4185.full.pdf
Kwen-JenChangandPedroCuatrecasas. (1979). MultipleOpiateReceptors, 254(8),
2610–2618. Retrieved from
https://www.researchgate.net/profile/Pedro_Cuatrecasas/publication/22918290_
Multiple_Opiate_Receptors_Enkephalins_and_Morphine_bind_to_receptors_of_
different_speeificity/links/02e7e537456ec444f5000000/Multiple-OpiateReceptors-Enkephalins-and-Morphine-bin
Lalanne, L., Ayranci, G., Kieffer, B. L., & Lutz, P.-E. (2014). The kappa opioid
receptor: from addiction to depression, and back. Frontiers in Psychiatry, 5, 170.

94

https://doi.org/10.3389/fpsyt.2014.00170
Le Merrer, J., Becker, J. A. J., Befort, K., & Kieffer, B. L. (2009). Reward processing
by the opioid system in the brain. Physiological Reviews, 89(4), 1379–412.
https://doi.org/10.1152/physrev.00005.2009
Li, C. H., Chung, D., & Doneen, B. A. (1976). Isolation, characterization and opiate
activity of b-endorphin from human pituitary glands. Biochemical and
Biophysical Research Communications, 72(4), 1542–1547.
https://doi.org/10.1016/S0006-291X(76)80189-1
Li, G., Aschenbach, L. C., Chen, J., Cassidy, M. P., Stevens, D. L., Gabra, B. H., …
Zhang, Y. (2009). Design, synthesis, and biological evaluation of 6alpha- and
6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor
selective antagonists. Journal of Medicinal Chemistry, 52(5), 1416–27.
https://doi.org/10.1021/jm801272c
Li, S., Zhu, J., Chen, C., Chen, Y.-W., Kim Deriel, J., Ashby, B., & Liu-Chen, L.-Y.
(1993). Molecular cloning and expression of a rat K opioid receptor, 295, 629–
633. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1134604/pdf/biochemj001000015.pdf
Li, X., Angst, M. S., & Clark, J. D. (2001). A murine model of opioid-induced
hyperalgesia. Molecular Brain Research, 86(1–2), 56–62.
https://doi.org/10.1016/S0169-328X(00)00260-6
Lord, J. A. H., Waterfield, A. A., Hughes, J., & Kosterlitz, H. W. (1977). Endogenous
opioid peptides: multiple agonists and receptors. Nature, 267(5611), 495–499.
https://doi.org/10.1038/267495a0
Lorenzen, A., Fuss, M., Vogt, H., & Schwabe, U. (1993). Measurement of guanine

95

nucleotide-binding protein activation by A1 adenosine receptor agonists in
bovine brain membranes: stimulation of guanosine-5’-O-(3[35S]thio)triphosphate binding. Molecular Pharmacology, 44(1), 115–23.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8341267
Lutz, P.-E., & Kieffer, B. L. (2013). Opioid receptors: distinct roles in mood disorders.
Trends in Neurosciences, 36(3), 195–206.
https://doi.org/10.1016/j.tins.2012.11.002
Mahajan, S. D., Schwartz, S. A., Shanahan, T. C., Chawda, R. P., & Nair, M. P. N.
(2002). Morphine Regulates Gene Expression of α- and β-Chemokines and
Their Receptors on Astroglial Cells Via the Opioid μ Receptor. The Journal of
Immunology, 169(7). Retrieved from
http://www.jimmunol.org.proxy.library.vcu.edu/content/169/7/3589
Mansour, A., Fox, C. A., Akil, H., & Watson, S. J. (1995). Opioid-receptor mRNA
expression in the rat CNS: anatomical and functional implications. Trends in
Neurosciences, 18(1), 22–29. https://doi.org/10.1016/0166-2236(95)93946-U
Mansour, A., Taylor, L. P., Fine, J. L., Thompson, R. C., Hoversten, M. T., Mosberg,
H. I., … Akil, H. (1997). Key residues defining the mu-opioid receptor binding
pocket: a site-directed mutagenesis study. Journal of Neurochemistry, 68(1),
344–53. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8978745
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976).
The effects of morphine- and nalorphine- like drugs in the nondependent and
morphine-dependent chronic spinal dog. The Journal of Pharmacology and
Experimental Therapeutics, 197(3), 517–32. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/945347
Mayer, D. J., & Liebeskind, J. C. (1974). Pain reduction by focal electrical stimulation

96

of the brain: an anatomical and behavioral analysis. Brain Research, 68(1), 73–
93. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/4549764
Meng, F., Xie, G.-X., Thompson, R. C., Mansour, A., Goldsteint, A., Watson, S. J., &
Akil, H. (1993). Cloning and pharmacological characterization of a rat k opioid
receptor (guanine nucleotide-binding protein-coupled
receptor/dynorphin/cAMP/in situ hybridization). Pharmacology, 90, 9954–9958.
Retrieved from
http://www.pnas.org.proxy.library.vcu.edu/content/90/21/9954.full.pdf
Miller, L. L., Altarifi, A. A., & Negus, S. S. (2015). Effects of repeated morphine on
intracranial self-stimulation in male rats in the absence or presence of a noxious
pain stimulus. Experimental and Clinical Psychopharmacology, 23(5), 405–414.
https://doi.org/10.1037/pha0000042
Minami, M., Toya, T., Katao, Y., Maekawa, K., Nakamura, S., Onogi, T., … Satoh, M.
(1993). Cloning and expression of a cDNA for the rat k-opioid receptor. FEBS
Letters, 329(3), 291–295. https://doi.org/10.1016/0014-5793(93)80240-U
Mombaerts, P. (2004). Genes and ligands for odorant, vomeronasal and taste
receptors. Nature Reviews Neuroscience, 5(4), 263–278.
https://doi.org/10.1038/nrn1365
MUSTO, D. F. (1999). American Disease - Origins of Narcotic Control. AMERICAN
DISEASE - ORIGINS OF NARCOTIC CONTROL. Retrieved from
http://search.ebscohost.com/login.aspx?direct=true&db=sih&AN=SM010485&sit
e=ehost-live
Nestler, E. J. (1996). Under Siege: The Brain on Opiates. Neuron, 16(5), 897–900.
https://doi.org/10.1016/S0896-6273(00)80110-5
Nestler, E. J. (2013). Cellular basis of memory for addiction. Dialogues in Clinical

97

Neuroscience, 15(4), 431–43. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/24459410
NIDA. (2014). National Overdose Deaths - 2014, 2007–2012. Retrieved from
https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/national-overdosedeaths2015.pdf
Olmstead, M. C., & Franklin, K. B. (1997). The development of a conditioned place
preference to morphine: effects of microinjections into various CNS sites.
Behavioral Neuroscience, 111(6), 1324–34. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/9438801
Pan, Y.-X. (2003). Expression of opioid receptors in mammalian cell lines. Methods
in Molecular Medicine, 84, 17–28. https://doi.org/10.1385/1-59259-379-8:17
Pasternak, G. W., & Pan, Y.-X. (2013). Mu Opioids and Their Receptors: Evolution of
a Concept. Pharmacological Reviews, 65(4), 1257.
https://doi.org/10.1124/pr.112.007138
Pathan, H., & Williams, J. (2012). Basic opioid pharmacology: an update. British
Journal of Pain, 6(1), 11–6. https://doi.org/10.1177/2049463712438493
Pattinson, K. T. S. (2008). Opioids and the control of respiration. British Journal of
Anaesthesia, 100(6), 747–758. https://doi.org/10.1093/bja/aen094
Peng, J., Sarkar, S., & Chang, S. L. (2012). Opioid receptor expression in human
brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug
and Alcohol Dependence, 124(3), 223–8.
https://doi.org/10.1016/j.drugalcdep.2012.01.013
Pert, C. B., & Snyder, S. H. (1973). Opiate receptor: demonstration in nervous
tissue. Science (New York, N.Y.), 179(4077), 1011–1014.
https://doi.org/10.1126/science.179.4077.1011

98

Rossi, G. C., Standifer, K. M., & Pasternak, G. W. (1995). Differential blockade of
morphine and morphine-6 beta-glucuronide analgesia by antisense
oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in
rats. Neuroscience Letters, 198(2), 99–102. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/8592651
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016). Increases in Drug and OpioidInvolved Overdose Deaths-United States, 2010-2015. MMWR. Morbidity and
Mortality Weekly Report, 65(5051), 1445–1452.
https://doi.org/10.15585/mmwr.mm655051e1
Russo, S. J., & Nestler, E. J. (2013). The brain reward circuitry in mood disorders.
Nature Reviews Neuroscience, 14(9), 609–625. https://doi.org/10.1038/nrn3381
Satoh, M., & Minami, M. (1995). Molecular pharmacology of the opioid receptors.
Pharmacology & Therapeutics, 68(3), 343–364. https://doi.org/10.1016/01637258(95)02011-X
Schuckit, M. A. (2016). Treatment of Opioid-Use Disorders. New England Journal of
Medicine, 375(4), 357–368. https://doi.org/10.1056/NEJMra1604339
Selley, D. E., Breivogel, C. S., & Childers, S. R. (1993). Modification of G proteincoupled functions by low-pH pretreatment of membranes from NG108-15 cells:
increase in opioid agonist efficacy by decreased inactivation of G proteins.
Molecular Pharmacology, 44(4), 731–41. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/8232223
Selley, D. E., Cao, C. C., Liu, Q., & Childers, S. R. (2000). Effects of sodium on
agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO
cells and rat thalamus. British Journal of Pharmacology, 130(5), 987–96.
https://doi.org/10.1038/sj.bjp.0703382

99

Selley, D. E., Liu, Q., & Childers, S. R. (1998). Signal transduction correlates of mu
opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding
in mMOR-CHO cells and rat thalamus. The Journal of Pharmacology and
Experimental Therapeutics, 285(2), 496–505. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/9580589
Selley, D. E., Sim, L. J., Xiao, R., Liu, Q., & Childers, S. R. (1997). μ-Opioid
Receptor-Stimulated Guanosine-5′-O-(γ-thio)-triphosphate Binding in Rat
Thalamus and Cultured Cell Lines: Signal Transduction Mechanisms Underlying
Agonist Efficacy. Molecular Pharmacology, 51(1). Retrieved from
http://molpharm.aspetjournals.org/content/51/1/87.long
Shen, K. F., & Crain, S. M. (1989). Dual opioid modulation of the action potential
duration of mouse dorsal root ganglion neurons in culture. Brain Research,
491(2), 227–42. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2548663
Shippenberg, T. S., & Elmer, G. I. (1998). The Neurobiology of Opiate
Reinforcement. Critical Reviews in Neurobiology, 12(4), 267–303.
https://doi.org/10.1615/CritRevNeurobiol.v12.i4.10
Sim-Selley, L. J., Scoggins, K. L., Cassidy, M. P., Smith, L. A., Dewey, W. L., Smith,
F. L., & Selley, D. E. (2007). Region-dependent attenuation of mu opioid
receptor-mediated G-protein activation in mouse CNS as a function of morphine
tolerance. British Journal of Pharmacology, 151(8), 1324–33.
https://doi.org/10.1038/sj.bjp.0707328
Sim-Selley, L. J., Selley, D. E., Vogt, L. J., Childers, S. R., & Martin, T. J. (2000).
Chronic heroin self-administration desensitizes mu opioid receptor-activated Gproteins in specific regions of rat brain. The Journal of Neuroscience: The
Official Journal of the Society for Neuroscience, 20(12), 4555–62.

100

https://doi.org/20/12/4555 [pii]
Sim, L. J., Selley, D. E., & Childers, S. R. (1995). In vitro autoradiography of
receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5’[gamma-[35S]thio]-triphosphate binding. Proceedings of the National Academy
of Sciences of the United States of America, 92(16), 7242–6.
https://doi.org/10.1073/pnas.92.16.7242
Sim, L. J., Selley, D. E., Dworkin, S. I., & Childers, S. R. (1996). Effects of chronic
morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS
autoradiography in rat brain. The Journal of Neuroscience: The Official Journal
of the Society for Neuroscience, 16(8), 2684–92. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/8786444
Simon, E. J., Hiller, J. M., & Edelman, I. (1973). Stereospecific binding of the potent
narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proceedings of the
National Academy of Sciences of the United States of America, 70(7), 1947–9.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/4516196
Smith, T. H., Sim-Selley, L. J., & Selley, D. E. (2010). Cannabinoid CB1 receptorinteracting proteins: novel targets for central nervous system drug discovery?
British Journal of Pharmacology, 160(3), 454–66. https://doi.org/10.1111/j.14765381.2010.00777.x
Snyder, S. H., & Pasternak, G. W. (2003). Historical review: Opioid receptors.
Trends in Pharmacological Sciences, 24(4), 198–205.
https://doi.org/10.1016/S0165-6147(03)00066-X
Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009). Opioid dependence treatment:
options in pharmacotherapy. Expert Opinion on Pharmacotherapy, 10(11),
1727–40. https://doi.org/10.1517/14656560903037168

101

Surratt, C. K., Johnson, P. S., Moriwaki, A., Seidleck, B. K., Blaschak, C. J., Wang,
B., & Uhlg, G. R. (1994). Opiate Receptor CHARGED TRANSMEMBRANE
DOMAIN AMINO ACIDS ARE CRITICAL FOR AGONIST RECOGNITION AND
INTRINSIC ACTiviTY. THE JOURNAL OF BIOLOGICAL CHEMISTRY, 269(32),
20548–20553. Retrieved from http://www.jbc.org/content/269/32/20548.full.pdf
Tai, B.; Blaine, J. (1997). Naltrexone - An Antagonist Therapy for Heroin Addiction.
NIDA Meeting Summary, 2–13. Retrieved from
https://archives.drugabuse.gov/meetings/Naltrexone.html
Terashvili, M., Wu, H., Leitermann, R. J., Hung, K., Clithero, A. D., Schwasinger, E.
T., & Tseng, L. F. (2004). Differential Conditioned Place Preference Responses
to Endomorphin-1 and Endomorphin-2 Microinjected into the Posterior Nucleus
Accumbens Shell and Ventral Tegmental Area in the Rat. Journal of
Pharmacology and Experimental Therapeutics, 309(2). Retrieved from
http://jpet.aspetjournals.org/content/309/2/816
Terenius, L. (1972). Specific uptake of narcotic analgesics by subcellular fractions of
the guinea-pig ileum. Acta Pharmacologica et Toxicologica, 31, 50–50.
Terenius, L. (1973). Characteristics of the???Receptor??? for Narcotic Analgesics in
Synaptic Plasma Membrane Fraction from Rat Brain. Acta Pharmacologica et
Toxicologica, 33(5–6), 377–384. https://doi.org/10.1111/j.16000773.1973.tb01539.x
Traynor, J. R., & Elliott, J. (1993). δ-Opioid receptor subtypes and cross-talk with μreceptors. Trends in Pharmacological Sciences, 14(3), 84–86.
https://doi.org/10.1016/0165-6147(93)90068-U
Traynor, J. R., & Nahorski, S. R. (1995). Modulation by mu-opioid agonists of
guanosine-5’-O-(3-[35S]thio)triphosphate binding to membranes from human

102

neuroblastoma SH-SY5Y cells. Molecular Pharmacology, 47(4), 848–54.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7723747
Tuteja, N. (2009). Signaling through G protein coupled receptors. Plant Signaling &
Behavior, 4(10), 942–7. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/19826234
Vallejo, R., de Leon-Casasola, O., & Benyamin, R. (2004). Opioid therapy and
immunosuppression: a review. American Journal of Therapeutics, 11(5), 354–
365. https://doi.org/00045391-200409000-00005 [pii]
van Dorp, E. LA, Yassen, A., & Dahan, A. (2007). Naloxone treatment in opioid
addiction: the risks and benefits. Expert Opinion on Drug Safety, 6(2), 125–132.
https://doi.org/10.1517/14740338.6.2.125
van Ree, J. M., Gerrits, M. A. F. M., & Vanderschuren, L. J. M. J. (1999). Opioids,
Reward and Addiction: An Encounter of Biology, Psychology, and Medicine.
Pharmacological Reviews, 51(2). Retrieved from
http://pharmrev.aspetjournals.org/content/51/2/341#sec-38
Volkow, N. D. (2012). Principles of Drug Addiction Treatment: A Research-Based
Guide. National Institute on Drug Abuse, 1–43. https://doi.org/NIH Publication
No. 12–4180
Vonvoigtlander, P. F., Lahti, R. A., & Ludens, J. H. (1983). U-50,488: a selective and
structurally novel non-Mu (kappa) opioid agonist. Journal of Pharmacology and
Experimental Therapeutics, 224(1). Retrieved from
http://jpet.aspetjournals.org.proxy.library.vcu.edu/content/224/1/7
Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004). Opioid Receptors. Annual
Review of Biochemistry, 73(1), 953–990.
https://doi.org/10.1146/annurev.biochem.73.011303.073940

103

Wang, J. B., Imai, Y., Epplert, C. M., Gregor, P., Spivak, C. E., & Uhl, G. R. (1993).
,u opiate receptor: cDNA cloning and expression. Neurobiology, 90, 10230–
10234. Retrieved from
http://www.pnas.org.proxy.library.vcu.edu/content/90/21/10230.full.pdf
Xu, H., Lu, Y.-F., Partilla, J. S., Zheng, Q.-X., Wang, J.-B., Brine, G. A., … Rothman,
R. B. (1999). Opioid peptide receptor studies, 11: Involvement of Tyr148,
Trp318 and His319 of the rat u-opioid receptor in binding of u-selective ligands.
Synapse, 32(1), 23–28. https://doi.org/10.1002/(SICI)10982396(199904)32:1<23::AID-SYN3>3.0.CO;2-N
Xu, W., Ozdener, F., Li, J.-G., Chen, C., de Riel, J. K., Weinstein, H., & Liu-Chen, L.Y. (1999). Functional role of the spatial proximity of Asp114(2.50) in TMH 2 and
Asn332(7.49) in TMH 7 of the u-opioid receptor. FEBS Letters, 447(2–3), 318–
324. https://doi.org/10.1016/S0014-5793(99)00316-6
Yan, K., Gao, L.-N., Cui, Y.-L., Zhang, Y., & Zhou, X. (2016). The cyclic AMP
signaling pathway: Exploring targets for successful drug discovery (Review).
Molecular Medicine Reports, 13(5), 3715–23.
https://doi.org/10.3892/mmr.2016.5005
Yuan, Y., Li, G., He, H., Stevens, D. L., Kozak, P., Scoggins, K. L., … Zhang, Y.
(2011). Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine
derivatives as novel leads to development of mu opioid receptor selective
antagonists. ACS Chemical Neuroscience, 2(7), 346–51.
https://doi.org/10.1021/cn2000348
Yuan, Y., Zaidi, S. A., Stevens, D. L., Scoggins, K. L., Mosier, P. D., Kellogg, G. E.,
… Zhang, Y. (2015). Design, syntheses, and pharmacological characterization
of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3’-

104

carboxamido)morphinan analogues as opioid receptor ligands. Bioorganic &
Medicinal Chemistry, 23(8), 1701–15. https://doi.org/10.1016/j.bmc.2015.02.055
Zachariou, V., Bolanos, C. A., Selley, D. E., Theobald, D., Cassidy, M. P., Kelz, M.
B., … Nestler, E. J. (2006). An essential role for DeltaFosB in the nucleus
accumbens in morphine action. Nature Neuroscience, 9(2), 205–211.
https://doi.org/10.1038/nn1636
Zachariou, V., Liu, R., LaPlant, Q., Xiao, G., Renthal, W., Chan, G. C., … Nestler, E.
J. (2008). Distinct roles of adenylyl cyclases 1 and 8 in opiate dependence:
behavioral, electrophysiological, and molecular studies. Biological Psychiatry,
63(11), 1013–21. https://doi.org/10.1016/j.biopsych.2007.11.021
Zaidi, S. A., Arnatt, C. K., He, H., Selley, D. E., Mosier, P. D., Kellogg, G. E., &
Zhang, Y. (2013). Binding mode characterization of 6α- and 6β-N-heterocyclic
substituted naltrexamine derivatives via docking in opioid receptor crystal
structures and site-directed mutagenesis studies: Application of the “message–
address” concept in development of mu opio.
https://doi.org/10.1016/j.bmc.2013.08.042
Zangen, A., Ikemoto, S., Zadina, J. E., & Wise, R. A. (2002). Rewarding and
Psychomotor Stimulant Effects of Endomorphin-1: Anteroposterior Differences
within the Ventral Tegmental Area and Lack of Effect in Nucleus Accumbens.
Journal of Neuroscience, 22(16). Retrieved from
http://www.jneurosci.org/content/22/16/7225
Zhang, R., & Xie, X. (2012). Tools for GPCR drug discovery. Acta Pharmacologica
Sinica, 33(3), 372–84. https://doi.org/10.1038/aps.2011.173
Zhang, Y., Landthaler, M., Schlussman, S. D., Yuferov, V., Ho, A., Tuschl, T., &
Kreek, M. J. (2009). Mu opioid receptor knockdown in the substantia

105

nigra/ventral tegmental area by synthetic small interfering RNA blocks the
rewarding and locomotor effects of heroin. Neuroscience, 158(2), 474–483.
https://doi.org/10.1016/j.neuroscience.2008.09.039

106

